

Review Article

NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer

 Fernando J. Velloso^{1,2}, Marina Trombetta-Lima², Valesca Anschau³, Mari C. Sogayar^{2,4} and  Ricardo G. Correa⁵

¹Department of Pharmacology, Physiology and Neuroscience, Rutgers-New Jersey Medical School Newark, NJ, U.S.A.; ²Cell and Molecular Therapy Center (NUCEL), Internal Medicine Department, School of Medicine, University of São Paulo (USP), São Paulo, SP, Brazil; ³Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia 46980, Spain; ⁴Biochemistry Department, Chemistry Institute, University of São Paulo, São Paulo, Brazil; ⁵NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, U.S.A.

Correspondence: Fernando J. Velloso (fernando.velloso@rutgers.edu) or Ricardo G. Correa (rcorrea@sbsdsccovery.org)



Innate immunity comprises several inflammation-related modulatory pathways which receive signals from an array of membrane-bound and cytoplasmic pattern recognition receptors (PRRs). The NLRs (NACHT (NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription activator), HET-E (incompatibility locus protein from *Podospora anserina*) and TP1 (telomerase-associated protein) and Leucine-Rich Repeat (LRR) domain containing proteins) relate to a large family of cytosolic innate receptors, involved in detection of intracellular pathogens and endogenous byproducts of tissue injury. These receptors may recognize pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs), activating host responses against pathogen infection and cellular stress. NLR-driven downstream signals trigger a number of signaling circuitries, which may either initiate the formation of inflammasomes and/or activate nuclear factor κ B (NF- κ B), stress kinases, interferon response factors (IRFs), inflammatory caspases and autophagy. Disruption of those signals may lead to a number of pro-inflammatory conditions, eventually promoting the onset of human malignancies. In this review, we describe the structures and functions of the most well-defined NLR proteins and highlight their association and biological impact on a diverse number of cancers.

NOD-like receptors

The innate immune system is our first line of defense against infections from an enormous diversity of microbes and viruses. The human innate immunity relies on a wide range of receptors and complex downstream networks which respond against infectious pathogens. Activation of these immune pathways leads to a broad range of pro- and/or anti-inflammatory signals, including the secretion of interferons, tumor necrosis factors and cytokines [1]. Disruption in the balance of these signals may lead to chronic inflammatory states and directly affect cellular processes, such as cell cycle progression and apoptosis, creating a background context for the rise of maladies, such as cancer [1,2].

In humans, innate immune receptors are classified into several families [3]. Amongst the most well-characterized receptors are the TLRs (Toll-like Receptors) and NOD-like receptors (NLRs) [NACHT (NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription activator), HET-E (incompatibility locus protein from *Podospora anserina*) and TP1 (telomerase-associated protein), and Leucine-Rich Repeat (LRR) domain containing proteins] [4–6]. While TLRs act as surface receptors found in cell and organelle (endosome) membranes, the NLRs are cytosolic receptors involved in the detection of intracellular pathogens and endogenous byproducts of tissue injury [7]. The NLRs are also known as a subgroup of pattern recognition receptors (PRRs), which act as innate immunity ‘sensors’ of pathogen-associated

Received: 16 January 2019
Revised: 04 March 2019
Accepted: 05 March 2019

Accepted Manuscript Online:
05 March 2019
Version of Record published:
09 April 2019

molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) [8,9]. Typically, the PAMPs recognized by NLRs are bacterial cell-wall derivatives [10], microbial toxins [11], viruses [12] or even whole pathogenic microbial organisms [13]. The DAMPs are host-derived molecules released by injured cells, including extracellular ATP [14], hyaluronan [15] and monosodium urate (MSU) [16]. Therefore, NLRs act as key activators of innate immune responses which, upon detection of cell damage and infections, may lead to the expression and/or activation of stress kinases, interferon response factors (IRFs) and inflammatory caspases [17–21].

NLR protein structure and subfamilies

A number of NLR homologs have been described in both vertebrate and invertebrate species [22]. In humans, the NLR protein family comprises 22 members [23–25]. All NLR proteins share a typical architecture, including: (i) a centrally located nucleotide-binding NACHT domain, which mediates self-oligomerization and is essential for ATP-dependent NLR activation; (ii) an N-terminal effector domain, which interacts with adaptor molecules and downstream effectors to mediate signal transduction; and (iii) a C-terminal region, comprising variable numbers of LRR domains, involved in the recognition of molecular patterns (Figure 1) [4]. Specifically, human NLRs are divided into four subfamilies, according to the nature of their N-terminal regions. These regions may contain (i) an acidic transactivation domain (AD) (NLRA subfamily), (ii) a baculoviral inhibitory repeat-like domain (BIR) (NLRB subfamily), (iii) a caspase activation and recruitment domain (CARD) (NLRC subfamily) or (iv) a pyrin domain (PYD) (NLRP subfamily) (Figure 1) [1,4,8,17,21,24].

The NLRA subfamily comprises a sole member, namely: the Class II Major Histocompatibility Complex Transactivator (CIITA). Apart from the AD domain, CIITA displays four LRRs and a GTP binding domain (Figure 1). GTP binding facilitates the protein transport into the nucleus, where it acts as a positive regulator of class II major histocompatibility complex gene transcription (Figure 2) [26]. In this case, transcriptional activation is not achieved through DNA binding, but via an intrinsic acetyltransferase (AT) activity [27,28]. Similarly, the NLRB subfamily comprises only one member, namely, the NLR Family Apoptosis Inhibitory Protein (NAIP). NAIP is an anti-apoptotic protein which acts by inhibiting (i) the activities of Caspase (CASP) 3 (CASP3), CASP7 and CASP9 [29], (ii) the autocleavage of pro-CASP9 and (iii) the cleavage of pro-CASP3 by CASP9 [30]. NAIP is a mediator of neuronal survival in several pathological conditions, preventing apoptosis induced by a variety of signals [31].

NLRC is the second largest subfamily of NLRs, consisting of six members: nucleotide oligomerization domain 1 (NOD1) (NLRC1), nucleotide oligomerization domain 2 (NOD2) (NLRC2), NLRC3, NLRC4, NLRC5, and NLRX1. The NLRC3, NLRC5 and NLRX1 members are classified in the NLRC subfamily due to their homology and phylogenetic relationships, although their N-terminal domains have not been fully characterized yet [32]. NOD1 and NOD2 (Nucleotide-Binding Oligomerization Domain-Containing Proteins 1 and 2) are considered as the founding NLRs as well as the two major members of the NLRC subfamily [33]. NOD1 and NOD2 recognize intracellular bacterial components, which enter the cell either via direct bacterial invasion or by other cellular uptake mechanisms [34,35]. NOD1 and NOD2 contain, respectively, one and two N-terminal oligomerization CARD domains and detect distinct motifs of peptidoglycans (PGNs) [36,37]. NOD1 recognizes D- γ -glutamyl-meso-DAP (L-Ala- γ -D-Glu-meso-diaminopimelic acid) (iE-DAP (D- γ -glutamyl-meso-DAP)) dipeptides, which are found in PGNs from all Gram-negative and some Gram-positive bacteria, while NOD2 recognizes the muramyl dipeptide (MDP) structure found in almost all bacterial types [33,36–38]. Therefore, NOD2 acts as a broader sensor of bacterial infection, while NOD1 recognizes a more specific subset of bacterial strains.

The NLRP subfamily of receptors consist of 14 members, characterized by the presence of an N-terminal pyrin (PYD) effector domain [39] which possesses a conserved sequence motif found in more than 20 human proteins, with functions in apoptotic and inflammatory signaling [8,39]. Within this subfamily, at least six receptors (NLRP1, NLRP3, NLRP6, NLRP7, NLRP12, NLRC4) have been reported to operate through formation of inflammasome complexes [39]. These NLRPs recognize various ligands originated from microbial pathogens (PGN, flagellin, viral RNA, fungal hyphae etc.), host cells (cholesterol crystals, uric acid etc.), and environmental sources (alum, asbestos, silica, alloy particles, UV radiation, skin irritants etc.) [8]. Studies have shown that *NLRP* genes play important roles in both the innate immune system and mammalian reproduction [8,40], suggesting that NLRPs might play a role in oogenesis and early preimplantation embryogenesis [8,40].

NLR signaling and inflammasome-related pathways

NLR activation is translated through distinct subpathways to achieve pro- or anti-inflammatory responses (Figure 2). The downstream signals involved are modulated by the type of ligands bound to the NLR and may also depend on the cellular context. For instance, NOD1 and NOD2 receptors bind to the membrane of early endosomes in the cytoplasm,




Figure 1. Protein structure representation of each NLR subfamily

Respective domains are indicated as follows: **CARD**: Caspase recruitment domain; **AD**: Acidic transactivation domain; **NACHT**: NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription activator), HET-E (incompatibility locus protein from *Podospora anserina*) and TP1 (telomerase-associated protein); **BIR**: Baculoviral inhibitory repeat-like domain; **X**: Unknown; **PYD**: Pyrin domain. Green open circles represent **LRR** (Leucine-rich repeat).

specifically interacting with the actin cytoskeleton in order to maintain an inactive state [41,42]. PGNs that are transported through the membrane [43–48] are promptly recognized by these NOD receptors. Ligand-bound NOD1 and NOD2 self-oligomerize through CARD–CARD interactions, using the endosomal membrane as a scaffold for the assembly of signaling complexes [46,49]. Oligomerized NODs send signals via the serine/threonine receptor-interacting protein 2 (RIP2) kinase [50], which, in turn, mediates ubiquitination of the nuclear factor κ B (NF- κ B) essential modulator (NEMO)/IKK γ complex and, consequently, activation of NF- κ B and production of inflammatory cytokines [4,51,52]. Furthermore, poly-ubiquitinated RIP2 also recruits TAB (TGF- β -activated kinase 1 and MAP3K7-binding protein) and its associated kinase TAK1 (TGF- β -activated kinase 1) [53,54]. TAK1 is a downstream activator of stress kinase, mitogen-activated protein kinase (MAPK) cascades, which activate JNK (c-Jun N-terminal kinase) and p38 MAPK toward activator protein 1 (AP-1) transcriptional activity [38,55,56].

Both NOD1 and NOD2 also activate the host response through an alternate pathway, independent of RIPK2 and NF- κ B signaling [21]. These receptors can detect intracellular bacteria which cross the plasma membrane and then recruit the autophagic essential adapter protein ATG16L1 to the bacterial entry site, promoting highly specific




Figure 2. NLR signaling pathways (related to prototypical members of each subfamily) and their correlation with cancer
 Lightning arrows indicate specific signaling nodes or receptor(s) for which gene mutations or alterations in expression levels have been reported in association with major types of cancer (adjacent boxes).

lysosome-mediated degradation of the invading microbe by the autophagic machinery [21,57–59]. In addition to detecting bacterial components, NOD1 and NOD2 receptors also monitor the cytoplasmic environment, responding to cytoskeleton perturbations and ER stress [60,61], which, ultimately, activate autophagy [62–64] and NF-κB-driven inflammation [61,65,66]. This effect allows these NOD receptors to respond to pathogens that do not produce specific PGNs [67].

Inflammasome-forming NLRs

The inflammasome is a multiprotein intracellular complex, which is frequently formed in response to several pathophysiological stimuli [67]. Despite its cytosolic localization, inflammasome structures are capable of launching an effective immune response against bacteria, fungi and viruses [68]. Indeed, inflammasome activation is an essential component of the innate response, playing a critical role in clearance of pathogenic insults and/or damaged cells [69].

In brief, the inflammasome structure includes: a sensor (NLR), an adaptor protein (ASC (apoptosis-associated speck-like protein containing CARD)) and an effector molecule (pro- CASP1) [70]. ASC is a bipartite protein consisting of a PYD and a caspase recruitment domain (CARD) [39,71]. In resting cells, caspase-1 is present in a catalytically inactive pro-form (zymogen) called pro-caspase-1 [72]. Caspases have long been established as executioners of the apoptotic response, also contributing to inflammasome activation [69].

The inflammasome activation initiates through the auto-coactivation of caspase-1, resulting in cleavage of pro-interleukin-1 β (pro-IL-1 β) and pro-interleukin-18 (pro-IL-18) [73,74] into their mature and active forms (IL-1 β and IL-18, respectively). The secretion of these cytokines may lead to pyroptosis, a term used to describe the inherently inflammatory process of CASP1-dependent programmed cell death [75,76]. Inflammasome-independent sources of IL-1 β have also been suggested to contribute to inflammatory disease pathogenesis; however, very little is known about the molecular regulation of these pathogenic pathways [77].

As previously indicated, several NLRs play a role in the formation of inflammasomes, namely: NLRP1, NLRP3 and NLRC4 [70]. Other less characterized inflammasome structures include NLRP2, NLRP6, NLRP7, NLRP12, as well as AIM2-like receptor (ALR) proteins [78]. Interferon γ -inducible protein 16 (IFL16) has also been suggested to assemble inflammasomes and induce caspase-1 activation in macrophages, indicating differential functions of IFL16, depending on the type of cell infected [79].

NLRP1 was the first NLR family member reported to form an inflammasome complex [80]. NLRP1 has been described to bind directly to its ligand MDP *in vitro*, with this interaction apparently being sufficient to activate the inflammasome assembly [70]. Genetic variation in the human *Nlrp1* gene has been linked to increased susceptibility to certain autoimmune diseases [81], systemic lupus [82] and cancer [179]. Studies have also demonstrated a genetic association of polymorphisms in *Nlrp1* gene in driving the tumorigenic process, which leads to an increase in the production of downstream mediators (i.e. CASP1 and IL-1 β) in malignant melanoma [83].

NLRP1-like genes are found in most, if not all, mammalian species for which a genome has been sequenced, including primates, rodents, ungulates and marsupials [84]. Humans express only one *NLRP1* gene, while the mouse genome contains three *Nlrp1* paralogs named *Nlrp1a*, *Nlrp1b* and *Nlrp1c* [79]. *Nlrp1a* and *Nlrp1b* contain all domains characteristic of murine NLRs, contrary to the *Nlrp1c* protein which is truncated so they lack the CARD domains [85]. The murine NLRP1b is involved in the mechanism by which *Bacillus anthracis* infection activates caspase-1 [86]. NLRP1b also serves as an inflammasome sensor for *Toxoplasma gondii*, leading to an inflammasome response in rats and, consequently, limiting parasite load and dissemination [87]. Still, more studies are warranted to describe the precise mechanism of *T. gondii* recognition by NLRP1b.

To date, NLRP3 (also known as cryopyrin and NALP3) is the most fully characterized member of the NLRs family [88]. The NLRP3 inflammasome is activated by a number of factors, which include: Gram-positive bacteria, viruses (such as influenza), fungi and protozoa, toxins (such as hemolysin), ATP, potassium efflux, and reactive oxygen species (ROS) [70,89–91]. In addition to the microbial and endogenous activators mentioned above, RNA and mitochondrial DNA have also been described as NLRP3 activators [92]. NLRP3 lacks a CARD, therefore, cannot recruit procaspase-1 without the presence of the adaptor molecule ASC [73]. NLRP3 interacts with ASC via PYD homophilic interactions [73]. Some studies link various adaptor proteins, such as guanylate-binding protein (GBP) [93,94], thioredoxin (TRX)-interacting protein (TXNIP) [89], amongst others shown to be critical for mammalian host defense. Altogether, the NLRP3 inflammasome integrates multiple signals to protect the host against different forms of cellular stress [95]. Nevertheless, the mechanisms governing the formation and activation of the NLRP3 inflammasomes, in certain cellular contexts, still deserve further investigation.

NLRC4 is also an important sensor for the activation of caspase-1, particularly in macrophages infected with *Salmonella* strains [96]. This sensor is typically activated by a more streamlined set of ligands, which includes bacterial flagellin and components of the bacterial T3SS (Type 3 secretion system proteins) [97]. NLRC4 appears to detect these ligands by recognizing pathogen derivatives, which are secreted into the host cell cytosol by certain bacterial strains [84].

Impact of NLRs on cancer

Chronic inflammation and cancer onset

Inflammation has a dual role in cancer onset and progression. Pro-inflammatory condition has been described as a crucial state for cancer onset, progression, angiogenesis, and metastasis [98–100], being related to chronic low-grade activation of the immune system as a result of the production of several downstream pro-inflammatory factors [101]. On the other hand, immunosurveillance can prevent cancer onset and limit tumor growth [102,103].

Biomolecules that are produced by tumor-infiltrating immune cells, such as cytokines, proteases, reactive oxygen and nitrogen species, can influence the microenvironment and act as intermediates in these pathological processes [104–106]. The microenvironmental changes caused by the immune infiltrate include alterations (i) in the tumoral

extracellular matrix and (ii) in the interaction between the different cell populations of the tissue, resulting in epigenetic modifications, epithelial–mesenchymal transition (EMT), oncogenes expression promotion and silencing of tumor suppressors [107–110]. Collectively, these alterations may orchestrate cell growth and survival, migration and/or angiogenesis, therefore promoting tumor progression and metastasis [111–113].

One of the most prominent cascades involved in tumor promotion is NF- κ B, a key pathway in innate immunity and inflammation, which frequently appears as an interesting therapeutic target [114,115]. Directly linked to NF- κ B, inflammasomes and their effector proteins are associated with different chronic pro-inflammatory conditions, and can either promote tumorigenesis or act as key players in immunosurveillance [116,117]. Interestingly, NF- κ B also exerts a critical regulatory role during development. Manipulation of NF- κ B members in a diverse range of animal models results in severe developmental defects during embryogenesis, very often leading to embryonic lethality [118]. For instance, inactivation of the NF- κ B pathway in chicks induces functional alterations of the apical ectodermal ridge, which mediates limb outgrowth [119,120]. In mice, the absence of NF- κ B activity leads to prenatal death due to defects in organogenesis and endoderm progression [121,122]. One major protein complex of this pathway, known as I κ B kinase (IKK (inhibitor of nuclear factor κ B kinase)), directly regulates NF- κ B activation also during development of early vertebrates [123]. The IKK complex is mainly composed by two catalytic subunits (IKK1 and IKK2) and one scaffolding molecule (NEMO). IKK2 is the major cytokine-responsive I κ B kinase [124,125] and, contrarily, IKK1 seems to be a repressor of NF- κ B activity in certain biological and cell-specific conditions [123]. For instance, *Ikk1* knockdown in zebrafish embryos leads to head-to-tail malformations due to up-regulation of NF- κ B-responsive genes and NF- κ B-dependent apoptosis [123]. Conversely, *ikk1* overexpression leads to midline structure defects (*no tail*-like phenotype) associated with the repression of NF- κ B activity [126]. Mechanistically, *Ikk1* seems to sequester the non-catalytic subunit NEMO from active IKK complexes, therefore blocking NF- κ B activation. Indeed, truncation of the NEMO-binding domain (NBD) in *Ikk1*, as well as increased availability of NEMO *in vivo*, is able to rescue the *Ikk1* overexpression phenotype [123]. Altogether, the significance of NF- κ B during early development certainly justifies the biological impact of this pathway in the onset and progression of various proliferative diseases, including cancer.

Here, we briefly discuss the inflammation mechanisms driven by distinct NLRs and their association with a substantial number of relevant malignancies. A snapshot of major cancer types associated with each NLR is shown in Figure 2, while a list of reports linking NLRs to a number of cancers is presented in Tables 1 and 2.

NLRA-associated cancers

B-cell lymphoma

B-cell lymphomas comprise approximately 85% of all non-Hodgkin's lymphomas (NHL), amongst which the primary mediastinal large B-cell lymphoma (PMBCL), a subtype of diffuse large B-cell lymphoma (DLBCL), sums up approximately 10% of the cases [127]. The incidence of PMBCL is higher in young adults and adolescents, with a metastatic potential to invade surrounding tissues [127]. Analysis of the *CIITA* sequence in PMBCL patient samples revealed the presence of structural genomic rearrangements, missense, nonsense, and frameshift mutations in 53% of the clinical cases [128]. These alterations led to decreased CIITA protein levels and, consequently, suppression of MHCII on the cell surface [128]. A similar study described that genomic breaks in the *CIITA* locus were present in 38% of the PMBCL samples and 15% of classical Hodgkin lymphoma (cHL) [129]. These alterations in *CIITA* sequence are associated with the down-regulation of surface MHC II, and increased expression of ligands of the receptor molecule programmed cell death 1, programmed death ligand 1 (PDL1) and programmed death ligand 2 (PDL2) [129]. These data suggest that *CIITA* has an essential role in PMBCL progression [128,129].

NLRB-associated cancers

Breast cancer

Breast cancer is the most prevalent cancer in women, accounting for 29% of all diagnosed cancers in females [130]. Little is known about NAIP's role in breast cancer, but *NAIP* mRNA levels have been well detected in tumor samples, while no expression is observed in control tissues [131]. In addition, *NAIP* expression in these malignant tissues is correlated with tumor size, but not with relapse-free survival [131]. More mechanistic studies are still warranted to confirm whether NAIP is relevant to breast cancer biology.

Colorectal cancer

Colorectal cancer (CRC) has the third highest cancer incidence worldwide, accounting for 9% of all cases, and is the fourth cause of death by cancer [132,133]. NAIP might also play an important role in preventing CRC onset [134]. Not only *NAIP* expression in colon cancer samples was found to be lower than in normal mucosa [135] but also,

Table 1 Summary of reported associations between members of NLRs subfamilies A, B, and C, and cancer progression

NRL subfamily	Member	Associated cancer	Associated phenotype	Molecular mechanisms	References	
NLRA	CIITA	Primary mediastinal B-cell lymphoma	Tumoral immune evasion	Decrease in surface MHC II and increase in CD274/PDL1 and CD273/PDL2	[128,129]	
NLRB	NAIP	Breast	Higher expression in tumor samples	–	[131]	
		Colorectal	Lower expression in tumor samples; depleted mice are more susceptible to colitis-associated cancer	Increase in STAT3 expression and failure to activate p53	[134,135]	
		Prostate	Higher expression in advanced prostate cancer submitted to androgen deprivation therapy; possible contribution to docetaxel resistance	Expression is induced by NF-κB	[138]	
NLRC	NOD1	Breast	SNPs associates with a higher cancer risk; inhibits ER-dependent tumor growth; deficiency correlates with tumor growth, an increased sensitivity to estrogen-induced cell proliferation, and impaired Nod1-dependent apoptosis; reduced cell proliferation and increased clonogenic potential <i>in vitro</i>	Apoptosis mediated by caspase 8 in a RIP2-dependent mechanism	[142–146]	
		Colorectal	Expression in T cells is associated with reduced susceptibility to chemically induced colitis and tumorigenesis; limits inflammation and its induced tumorigenesis	Reduction of inflammation induced tumorigenesis in an IFNγ-mediated mechanism	[150]	
		Gastric	SNPs associated with <i>Helicobacter pylori</i> infection and gastric lesions; up-regulated upon <i>H. pylori</i> infection and associates with a higher inflammatory state in GC	Activation of TRAF3 and suppression of Cdx2	[160–162]	
	NOD2	Breast	SNPs associated with a higher cancer risk; reduced cell proliferation and increased clonogenic potential <i>in vitro</i>	–	[142,143,146]	
		Colorectal	Deficient expression associates with higher susceptibility to experimental models of CRC and induced instability in the composition of gut bacteria; limits inflammation and its induced tumorigenesis	Inhibition of NF-κB and MAPK pathways through the induction of IRF4	[156,157]	
		Gastric	SNPs associated with <i>H. pylori</i> infection and gastric lesions	–	[159]	
	NLRC3	Colorectal	Reduced expression correlated with cancer progression; suppression of cellular proliferation and induction of cell death	Inhibition of the PI3K-mTOR signaling pathway through interaction with PI3K, TRAF6, and mTOR, suppression of c-Myc activity, FoxO3a and FoxO1	[148,151]	
	NLRC4	Breast	Poor prognosis	–	Upon obesity, expression in myeloid cells leads to IL-1β expression and VEGFA-dependent angiogenesis	[141]
		Colorectal	Reduced expression correlates with cancer progression; mediates higher proliferation and apoptosis evasion during tumorigenesis in casp-1 deficient mice	–	[148]	
NLRC5	Colorectal	Reduced expression correlates to impaired CD8 ⁺ T-cell activation and poor patient prognosis; higher cancer risk	–	Impaired MHC I pathway	[149,153–155]	
	Gastric	Expression associated with lymph nodes and tumor node metastasis	–	–	[162]	

Abbreviations: Cdx2, caudal-related homeobox 2; CRC, colorectal cancer; ER, estrogen receptor; GC, gastric cancer; PDL1, programmed death ligand 1; PDL2, programmed death ligand 2; VEGFA, vascular endothelial growth factor A.

based on a model of colitis-associated cancer, mice lacking NAIP paralogs (Naip1-6) display a higher susceptibility for CRC in an inflammation-independent mechanism [134]. Furthermore, these knockout mice displayed increased *STAT3* expression and failed to activate p53 upon carcinogen exposure [134]. This suggests that NAIPs may act as tumor suppressors *in vivo* by inducing apoptosis in carcinogen-affected cells.

Table 2 Summary of reported associations between NLRP and atypical genes and cancer progression

NRL subfamily	Member	Associated cancer	Associated phenotype	Molecular mechanisms	References	
NLRP	NLRP1	Skin	Promotes migration, IL-1 β processing, evasion of apoptosis and hyperplasia	IL-1 β processing, Caspase-1 cleavage, inhibition of caspase-2, -3/7, and -9 activities	[209,210-212,214]	
		Prostate	Up-regulated in experimental model of inflammation by formalin injection <i>in situ</i>	Increase in IL-1 β , IL-18, and caspase-1 expressions	[205]	
		Cervix	SNP associated with lower oncogenesis related to HPV infection	–	[166]	
	NLRP3	Cervix	SNP associated with lower oncogenesis related to HPV infection, highly expressed in an inflammatory context upon LPS treatment	Caspase-1 cleavage, IL-1 β expression and processing	[166,167]	
		Colorectal	Expression in macrophages: promotes invasion, migration, metastasis of tumor cells	Expression in macrophages: leads to caspase-1 cleavage, NLRP3–ASC–caspase-1 complex formation, and IL-1 β processing and secretion	[169,171,173–175]	
			Expression in tumor cells: promotes EMT; depletion leads to higher tumor burden, liver metastasis, and impairment of NK cell maturation	Expression in tumor cells: promotes EMT in a caspase-1 independent mechanism through Snail1 expression; depletion leads to IL-18 impairment, and consequent IFN- γ and STAT1 inhibition		
		Gastric	SNPs associated with higher cancer risk; expression in macrophages was found to be associated with aggressiveness	IL-1 β secretion	[190]	
	Glioblastoma	Promotes EMT, higher migratory and invasive potential, proinflammatory signaling, IL-1 production, ionizing radiation (IR) treatment resistance, cellular senescence after IR, resistance to apoptosis	IL-1 β processing, AKT/PTEN pathway and Stat3 activation	[197–200]		
	NLRP6	Colorectal	Skin	Promotes migration, IL-1 β processing and hyperplasia	IL-1 β processing, Caspase-1 cleavage, NFK β pathway	[211,212,214]
			Associated with self-renewal of the colon epithelium upon injury, integrity and homeostasis of the epithelial barrier, depletion leads to higher tumor burden	Down-regulation of the cytokine IL-22BP in an IL-18-dependent mechanism, promotes inflammation through CCL-5, IL-18 and IL-6 pathway activation	[152,179,180]	
NLRP7	Endometrial	Correlates with depth of tumor invasion	–	[187]		
	Gastric	Deficiency associated with lymph node metastasis and poor overall survival	Senescence mediated by P21 and Cyclin D1	[191]		
NLRP12	Colorectal	Its depletion leads to higher tumor burden	Modulation of noncanonical NF- κ B through TRAF3 and NIF, AKT and ERK pathways	[181,182]		
	Gastric	SNPs associated with higher cancer risk	–	[189]		
Atypical	NWD1	Prostate	Expression correlates with tumor progression	Its expression is modulated by SRY Regulates PDEF expression Its depletion reduces AR levels and androgen-responsive genes	[219]	

Abbreviations: AR, androgen receptor; HPV, human papillomavirus; IL-22BP, IL-22 binding protein; LPS, lipopolysaccharide; NK cell, natural killer cell; PDEF, prostate-derived Ets factor; SRY, sex-determining region Y.

Prostate cancer

Prostate cancer (PCa) is the most common cancer in men [136,137]. Advanced PCa, submitted to androgen deprivation therapy, displays increased *NAIP* expression, which may possibly contribute to docetaxel resistance [138]. One possible explanation is that androgens generally inhibit responsive elements in NF- κ B transcription factors promoters, decreasing their expression [138,139]. Therefore, it was verified by chromatin immunoprecipitation (ChIP) that, upon hormonal deprivation, NF- κ B largely interacts with κ B-like sites along the *NAIP* locus to promote its transcription activation [138]. These data suggest that *NAIP* levels may correlate with drug resistance in the treatment of PCa, but further experiments are needed to explore the role of *NAIP* in these mechanisms.

NLRC-associated cancers

Breast cancer

Obesity has been associated with a poor prognosis of breast cancer patients, since adipose cells stimulate angiogenesis and synthesize estrogen, a primary female hormone that impacts tumor growth and metastatic potential [140]. For instance, in an orthotopic model, obese mice displayed higher tumor-infiltrating myeloid cells content and higher

tumor-angiogenesis [141]. Interestingly, myeloid cells from obese mice display increased *NLRC4* expression and, consequently, IL-1 β production. Cross-talk between tumor tissue and immune infiltrates also leads to vascular endothelial growth factor A (VEGFA)-mediated angiogenesis in an *NLRC4*-dependent manner, therefore driving disease progression [141].

A number of *NOD1* and *NOD2* SNPs have been associated with a higher risk of cancer development in many malignancies [142,143]. Although no tumor suppressor activity has been described for *NOD2*, *NOD1* seems to have important tumor suppressor activity in estrogen receptor (ER)-dependent breast cancer, using an SCID mice xenograft model [144]. In ER-positive MCF-7 cells, *NOD1* deficiency correlates with tumor growth, an increased sensitivity to estrogen-induced cell proliferation and impaired *Nod1*-dependent apoptosis. Correspondingly, in the same cells, *NOD1* overexpression inhibited ER-dependent tumor growth and reduced estrogen proliferative response *in vitro* [144]. Apparently, *Nod1*-dependent apoptosis is mediated by a caspase 8-cascade in an *RIP2*-dependent manner [145]. More recently, it has been described that overexpression of either *NOD1* or *NOD2*, in the triple negative Hs578T cells, is able to reduce cell proliferation but increase clonogenic potential *in vitro* [146]. The proteomic profile of these overexpressing cells suggests the involvement of several inflammation- and stress-related pathways (intersecting NF- κ B, PI3K and MAPK cascades) in the modulation of protein degradation processes, cell cycle and cellular adhesion [147]. The disruption of these critical systems suggests a functional link between *NOD1/NOD2* and the proliferation and migration of triple negative breast cancer cells [147]. Although *NOD1* tumor suppressive role is evidenced in ER-dependent tumors [144], both *NOD1* and *NOD2* appear to be relevant for the aggressive potential of breast cancer *in vitro*.

CRC

The expression of certain NLRs has also been found to be modulated in CRC [148–150]. A combined analysis of TCGA (<http://cancergenome.nih.gov>) and Oncomine (<https://www.oncomine.org>) datasets, with mRNA expression analysis of tissue samples, revealed that *NOD1* and *NOD2* expression is usually increased, while *NLRC3* and *NLRC4* expression is reduced in CRC [148]. Furthermore, TCGA data analysis revealed that *NLRC3* expression inversely correlates with the American Joint Committee CRC staging [148]. Based on this staging, CRC is classified from stage I to IV in which (i) stage I tumors have breached beyond the inner lining of the colon, (ii) stage II tumors invaded the muscular wall of the colon, (iii) stage III tumors have reached the lymph nodes and (iv) stage IV tumors have metastasized to other organs besides the lymph nodes [148]. This correlation might be explained by recent reports describing the link between *NLRC3* and the concomitant suppression of cellular proliferation and induction of cell death through the inhibition of the PI3K-mTOR signaling pathway in different node points [151]. Interestingly, *NLRC3* knockout mice, treated with azoxymethane and dextran sodium sulfate (colitis-associated CRC model), display an increased *C-MYC* expression and FoxO3a and FoxO1 phosphorylation (effectors of the PI3K-AKT pathways) [151]. Likewise, caspase-1-deficient mice submitted to the same treatments show increased epithelial cell proliferation in early stages of oncogenesis, and apoptosis evasion in additional stages in an *NLRC4*-dependent manner [152].

NLRC deficiencies are also correlated to immunosurveillance escape-mediated tumor progression [149]. Gene mutations, polymorphisms, loss of copy numbers, and methylation of the MHC class I transactivator *NLCR5* have been associated with MHC I pathway disruption and a higher cancer risk [149]. It is interesting to note a correlation between reduced *NLCR5* expression and higher CRC risk, especially in mismatch repair-deficient tumors [153–155]. Moreover, it has been proposed that reduced *NLRC5* expression also correlates to impaired CD8⁺ T-cell activation and poor patient prognosis [149].

Furthermore, *NOD1* expression in T cells has been associated with a reduced susceptibility to chemically induced colitis and subsequent tumorigenesis, by limiting inflammation-induced tumorigenesis in an IFN γ -dependent mechanism [150]. Similarly, *NOD2* deficient mice appear to be more susceptible to experimental models of CRC [156]. Both *NOD1* and *NOD2* can inhibit NF- κ B and MAPK pathways through induction of IRF4 [156] and, apparently, have a role in the suppression of inflammation-induced tumorigenesis [156]. Furthermore, *NOD2* deficient mice are seemingly more prone to colitis and colitis-related cancer due to induced instability in the composition of gut microbiome [157]. This increased susceptibility to inflammation could be prevented by (i) microbiota transplantation, (ii) antibiotics or (iii) anti-IL-6 neutralizing antibody treatment [157]. These findings reiterate the notion that NLRs also influence tissue microenvironment and suppress CRC tumorigenesis.

Gastric cancer

Helicobacter pylori infection is a strong risk factor for gastric cancer (GC) [158]. *NOD1*- and *NOD2*-specific SNPs have been associated with *H. pylori* infection and gastric lesions [159]. In this context, expression of the epithelial-specific transcription factor *CDX2* is known to contribute to intestinal metaplasia (an event that precedes

GC) and to be induced by *H. pylori* infection [160]. The NF- κ B pathway has been implicated in induction of *CDX2* expression [160]. In contrast, NOD1-dependent activation of TRAF3, a negative regulator of NF- κ B, may suppress *CDX2* expression [160]. This is somewhat contradictory to the findings in which, upon *H. pylori* infection, NOD1 is up-regulated and associated with a higher inflammatory state in GC [161].

NLRC5 expression has been correlated with lymph nodes and tumor node metastasis in GC [162]. As a result, *NLRC5* has been considered as an independent risk factor for the prognosis of GC patients [162]. The orchestrated expression of *NLRC5*, as well as of other NLRC proteins, may play an important role in GC onset, but more detailed studies are needed to better dissect their actual contribution to GC.

NLRP-associated cancers

Amongst the NLRP subfamily members, the role of NLRP3 in cancer is the most well characterized (extensively revised in [163]). Here, we describe some of the main findings linking NLRPs to different human malignancies.

Cervical cancer

Cervical cancer is the second most common cancer type in women [164]. It has been found that persistent Human Papillomavirus (HPV) infection, associated with chronic inflammation, may lead to cancer onset [165]. Particularly, polymorphisms in *NLRP1*, *NLRP3* and *IL-18* have been associated with a lower HPV persistence and associated oncogenesis [166]. Using an inflammation model, human cervical cancer cells, positive for HPV-16 and treated with lipopolysaccharide (LPS), have indeed displayed increased levels of NLRP3, IL-1 β , processed IL-1 β , and cleaved caspase-1 [167].

CRC

Inflammation is highly associated with the onset of CRC. Inflammatory bowel disease (IBD), which comprises diseases such as ulcerative colitis and Crohn's disease, is mainly a chronic inflammatory condition which is known to increase the overall risk of developing CRC by 4- to 20-fold [132]. NLRP3 has been proposed to be a link between IBD and CRC (reviewed in [168]). Interestingly, high-fat diet has also been associated with NLRP3 activation and increased tumor susceptibility [162,169]. High-fat diet leads to an increase in deoxycholic acid levels in the intestine, which, in turn, disrupts the cell monolayer integrity by decreasing the expression of the tight junction protein ZO-1 [170]. This disruption in the mucosal barrier leads to an increased tissue inflammation, mediated by NLRP3, and further polarization of M2 macrophages [162]. Likewise, azoxymethane-treated mice submitted to a cholesterol-rich diet show increased tissue inflammation and higher susceptibility to tumor development [169]. In fact, cholesterol inhibits the activity of AMPK α in macrophages, resulting in increased levels of mitochondrial ROS [169]. An oxidative microenvironment may then activate NLRP3, leading to (i) inflammasome formation, (ii) caspase-1 cleavage and (iii) IL-1 β processing and secretion [169]. This cascade of events can be partially reverted by NLRP3 depletion [169].

NLRP3 expression has also been found in macrophages infiltrated in CRC tissues, and the inhibition of NLRP3 pathway leads to decreased tumor cell migration, invasion and metastatic potential [171]. These data are supported by the evidence that treatment with a small-molecule AMPK activator (GL-V9), which acts as an anti-inflammatory molecule on macrophages, triggers autophagy and NLRP3 degradation, providing a protective effect against colitis and CRC [172].

Although *NLRP3* expression in tissue-infiltrated macrophages has been associated with higher susceptibility to CRC and its aggressiveness, its role in tumor cells is, at a first glance, controversial. NLRP3 has been found, for instance, to be highly expressed in the SW620 mesenchymal-like CRC cell line [173]. Moreover, HCT116 and HT29 epithelial-like CRC cell lines, when submitted to EMT through the treatment with TNF- α and TGF- β 1, displayed an increase in *NLRP3* expression mediated by NF- κ B [173]. In contrast, *NLRP3* or *CASP1* deficient mice are more susceptible to the CRC burden induced by azoxymethane-DSS-induced inflammation model [174]. This phenotype is associated with lower *IL-18* expression levels and, consequently, impairment of *IFN- γ* expression and suppression of STAT1 activation [174]. In addition, *NLRP3* knockout mice display augmented liver metastasis [175], which is also due to the impairment of IL-18 signaling. This suppression affects Fas ligand (*FasL*) expression in natural killer cells (NK cells), thus compromising their ability to kill FasL-sensitive tumor cells [175].

In accordance with the current data, *NLRP3* expression might be explored for the prevention of CRC. One example is its role as an effector of TRAIL (tumor necrosis factor related apoptosis-inducing ligand), an apoptosis-inducing protein whose use for cancer treatment has been currently evaluated [176–178]. In this context, mice submitted to the azoxymethane-DSS CRC model and treated with recombinant TRAIL displayed inhibition of macrophage recruitment to the damaged mucosa, therefore diminishing acute inflammation [176]. At the same time, TRAIL promoted tissue regeneration by NLRP3 activation, which induced IL-18 expression and promoted IL-1 β secretion and

caspase-1 cleavage [176]. These studies emphasize the multifunctional role of NLRP3, as well as the importance of the cross-talk between the different resident tissue cells and the CRC outcome.

Other members of the NLRP subfamily have also been related to CRC biology. For instance, NLRP6, typically produced by the stem-cell niche, acts on the self-renewal of the colon epithelium upon injury and, therefore, it is important for the integrity and homeostasis of the epithelial barrier [179]. Indeed, *NLRP6* deficient mice show impaired regeneration of the mucosa upon injury, and they are susceptible to colitis-associated tumor growth [179]. NLRP6 is involved in inflammation promotion by down-regulating the IL-22 binding protein (IL-22BP) which neutralizes IL-22 in an IL-18-dependent mechanism [180]. In addition, NLRP6 promotes inflammation through microbiota-induced activation of chemokine (C-C motif) ligand 5, IL-18 and IL-6 related pathways [69].

NLRP12 is another potential therapeutic target, since *NLRP12* knockout mice looks prone to colon inflammation and CRC, through enhanced activity of non-canonical NF- κ B, ERK and AKT pathways, in both macrophages and tumor cells [181,182]. Nevertheless, due to the dual role of inflammation in cancer development, further studies are still warranted to better explore the clinical potential of some inflammasome-related proteins.

Endometrial cancer

The incidence rates of endometrial cancer have increased during last few decades and, nowadays, is considered the sixth most common cancer in women [183]. Its occurrence is associated with precursor hyperplastic lesions in more than 40% of cases [184]. Although IL-1 has been described to have an important role in endometriosis (a chronic inflammatory condition in which endometrial tissue grows outside the uterine cavity) [185,186], little is known about the inflammasome's role in the development of this endometrial condition. The only available data so far refer to a statistical correlation observed between NLRP7 and the depth of the tumor invasion in the surrounding normal tissue [187], which is indeed promising but requires more detailed investigations.

GC

GC is the fourth most common type of cancer, and it is responsible for the second highest rate of cancer-related deaths [188]. Specific SNPs in some NLRP subfamily members, such as *NLRP3* and *NLRP12*, have been associated with increased risk of *H. pylori* infection (one of GCs most prominent risk factors) and also to GC itself [189]. *H. pylori*-challenged cells can lead to simultaneous down-regulation of *NLRP9* and *NLRP12* and up-regulation of the canonical NF- κ B pathway [189]. Indeed, NLRP12 is a known inhibitor of the NF- κ B pathway, and its inhibition might contribute to the maintenance of an active state of this signaling cascade [189].

NLRP3 expression in macrophages has been found to be associated with GC aggressiveness [190]. In a physiological scenario, the microRNA miR-22 (expressed in the gastric mucosa) inhibits *NLRP3* expression and suppresses inflammation [190]. *H. pylori* infection suppresses miR-22, increasing *NLRP3* expression which, in turn, leads to IL-1 β secretion and promotes the proliferation of epithelial cells and GC tumorigenesis [190]. Contrarily, it has been reported that *NLRP6* expression is reduced in ~75% of the primary GC cases, and is associated with lymph node metastasis and poor overall survival [191]. *NLRP6* expression may suppress cancer cell proliferation by inducing senescence in a mechanism mediated by p21 and cyclin D1. In fact, overexpression of *NLRP6*, along with the inactivation of NF- κ B and Mdm2, activates the p14ARF-p53 pathway and promotes senescence of GC cells [191]. This particular mechanism may be potentially explored for the GC treatment.

Glioblastoma multiforme

Glioblastoma multiforme (GBM), also known as Grade IV astrocytoma, is the most common type of brain tumors in adults, comprising approximately 17% of the cases [192,193]. GBMs are extremely aggressive tumors, displaying highly infiltrative growth patterns and a very poor prognosis, with a median overall survival of 15–18 months after diagnosis [192,194,195].

The tumor microenvironment plays a crucial role in GBM progression. In particular, the presence of activated microglial and macrophage cells are associated with higher aggressive phenotypes (reviewed in [196]). Amongst the soluble factors secreted by microglial cells, IL-1 is known to activate GBM cells, partially due to the activation of TGF β pathway, and also to alter their secretome, resulting in the up-regulation of interleukin-8 (IL-8) and C-C motif chemokine ligand 2 (CCL2), and the down-regulation of collagen type IV α 2 chain (COL4A2) [197]. In human GBM cell lines, NLRP3 is also responsible by IL-1 β processing [198]. IL-1 production in these cells leads to activation of the transcriptional factor Stat3, resulting in increased cellular migration and establishing a mesenchymal phenotype [198].

NLRP3 has been positively correlated to higher histological grades in astrocytomas [199]. *NLRP3* overexpression in human GBM cells promotes invasion, migration, proliferation, resistance to apoptosis and EMT via activation

of the AKT pathway [199]. In addition, *NLRP3* expression has been linked to resistance against ionizing radiation therapy, leading to an increased number of senescent cells after this treatment [200]. Interestingly, this phenotype is partially reverted by *NLRP3* inhibition [200]. Therefore, *NLRP3* looks like a promising therapeutic target, and the use of *NLRP3* inhibitors, such as β -Hydroxybutyrate or certain miRNAs, have been considered for GBM treatment [201,202].

PCa

Studies have shown that the presence of infiltrating immune cells in prostatic tissues is inversely correlated to PCa progression [203,204]. Prostatic inflammation, experimentally induced by intra-prostatic injection of formalin, leads to increased *NLRP1* expression and consequent increase in IL-1 β , IL-18 and caspase-1 levels [205]. Highly metastatic PCa cells (DU145 and PC-3) secrete IL-18 binding protein (IL-18BP) after IFN- γ stimulation [206]. Coincidentally, IL-18BP levels in patient sera have been correlated with PCa aggressiveness [206]. This suggests that IL-18 neutralization might be a mechanism by which PCa cells bypass immunosurveillance and promote tumor development.

Skin cancer

Approximately 2–3 million skin cancers cases are diagnosed each year and their incidence has increased over the last decades [207]. Skin tumors can be classified as non-melanomas (derived from keratinized epithelial cells) or melanomas (derived from melanocytes) [190,191]. Melanoma accounts for 2% of the cases, being the most aggressive type of skin cancer, accounting for almost 10000 deaths per year [207,208].

Although inflammation may contribute to defense mechanisms against tumor onset, chronic skin inflammation can promote the development of benign and malignant lesions. For instance, using organotypic *ex vivo* skin models, treatment with IL-1 leads to an increase in epidermal thickness due to the proliferation of keratin-10- and involucrin-positive keratinocytes in the basal layer [209]. This higher proliferation rate is accompanied by an increased expression of the stress markers, S100 calcium binding proteins A8/9 (*S100A8/9*) and S100 calcium binding protein A7 (*S100A7*), known to be highly expressed in skin cancers, suggesting that inflammasome-dependent IL-1 production may be sufficient to induce skin hyperplasia [209].

The skin typically displays high expression levels of *NLRP1*, and gain-of-function mutations along this gene can lead to skin hyperplasia, including multiple self-healing palmoplantar carcinoma (MSPC) and familial keratosis lichenoides chronica (FKLC) [209]. *NLRP1* knockdown in metastatic melanoma cell lines induces lower caspase-1 activity and IL-1 β production/secretion, but it also results in increased caspase-2, -3/7 and -9 activities, therefore promoting apoptosis [210]. Likewise, activation of *NLRP1*, but not of *NLRP3*, decreases caspase-2, -3/7, and -9 activities and consequent evasion from apoptosis [210].

Ultraviolet B (UVB) radiation is considered a major risk factor for skin cancer. Both *NLRP1* and *NLRP3* have been implicated in the first response to UVB in human keratinocytes [211,212]. UVB induces *NLRP1* and *NLRP3* expression, leading to inflammation onset through extensive IL-1 β secretion [211,212]. Furthermore, specific SNPs in both *NLRP1* and *NLRP3* have been associated with susceptibility to nodular melanoma [213]. More recently, CRISPR inactivation of both *NLRP* genes revealed that *NLRP1* is, in fact, the main responsible for the cellular pro-inflammatory response against UVB radiation [214]. Nevertheless, a compound isolated from *Nigella sativa* seeds, called thymoquinone (2-isopropyl-5-methyl benzo-1,4-quinone), was found to inhibit migration of melanoma cells through inhibition of *NLRP3* expression and its related cascade, leading to a decrease in caspase-1 cleavage as well as IL-1 and IL-18 levels [215]. This suggests that both *NLRP* proteins may be relevant for the onset and progression of skin cancer.

NLR-related proteins and cancer

PCa

Other cytosolic receptors, which are not fully categorized as NLRs but still share structural similarities, may also be of clinical relevance in the context of cancer development. For instance, *NWD1* (NACHT and WD repeat domain-containing protein 1) is an NLR-related protein which carries a conserved NACHT domain and WD40 repeats instead of LRRs at the C-terminus [216]. Sequence homology analysis suggests this protein may be a novel NLR family member [216]. *NWD1* also share homology with Apaf1 (Apoptotic peptidase activating factor 1), a cytoplasmic receptor that also possesses WD40 repeats instead of LRRs, and it is involved in caspase 9-mediated apoptosis [217,218]. It has been reported that *NWD1* expression elevates in the course of PCa progression. *In vitro* experiments demonstrated that sex-determining region Y (SRY) proteins may regulate the *NWD1* expression, which in turn regulate PDEF (prostate-derived Ets factor), a transcription factor which is known to bind and modulate the androgen receptor (AR). Furthermore, *NWD1* depletion reduces AR levels and androgen-responsive genes, suggesting a role for *NWD1* in PCa via AR deregulation [219].

Conclusion

Based on the data here described, we summarized how deregulation in the balance of NLR-related signals may lead to the onset of several types of cancer. Despite all the knowledge accumulated regarding these cytosolic receptors, the functional domains, ligand specificity and signal transduction events directed by each particular family member still remain to be better elucidated. At the same time, new atypical NLR members may continue to be uncovered, adding another layer of complexity to the studies involving innate immune sensors. A more in-depth understanding of how these receptors signal through different pathways, and how they interact to achieve a global impact in diverse pathologies, such as cancer, will be seminal to develop better diagnostic and prognostic tools, as well as more effective therapeutic strategies.

Funding

This work was supported by CAPES (Federal Agency for Superior Education and Training) research funding agency [grant number 88887.091759/2015-00 (to F.J.V.)]; FAPESP (São Paulo State Foundation for Research) [grant number 2016/05311-2 (to M.C.S.)]; CNPq (National Research Council) [grant number 148684/2013-0; 457201/2013-2 (to M.C.S.)]; BNDES (Brazilian National Bank for Economic and Social Development) [grant number 09.2.1066.1 (to M.C.S.)]; FINEP (Project Financing Agency) [grant number 01.06.0664.00; 01.08.0622.00 (to M.C.S.)]; MCTI (Science, Technology and Innovation Ministry) (to M.C.S.); MS-DECIT (Science and Technology Department of the Health Ministry) (to M.C.S.); and a Special Visiting Researcher (PVE) grant from the 'Science without Borders' Program (CAPES, Brazil) [grant number 88887.091759/2015-00 (to R.G.C.)].

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Abbreviations

AD, acidic transactivation domain; AR, androgen receptor; ASC, apoptosis-associated speck-like protein containing CARD; AT, acetyltransferase; CARD, caspase recruitment domain; CASP1, caspase 1; CIITA, class II major histocompatibility complex transactivator; CRC, colorectal cancer; DAMP, danger-associated molecular pattern; EMT, epithelial-mesenchymal transition; ER, estrogen receptor; FasL, Fas ligand; GBM, glioblastoma multiforme; GC, gastric cancer; HPV, human papillomavirus; IKK, inhibitor of nuclear factor κ B kinase; IRF, interferon response factor; I κ B, inhibitor of nuclear factor κ B; LRR, leucine-rich repeat; MAPK, mitogen-activated protein kinase; MDP, muramyl dipeptide; NAIP, NLR family apoptosis inhibitory protein; NACHT, NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription activator), HET-E (incompatibility locus protein from *Podospora anserina*) and TP1 (telomerase-associated protein); NEMO, NF- κ B essential modulator; NF- κ B, nuclear factor κ B; NLR, NACHT and LRR domain containing protein; NOD1, nucleotide oligomerization domain 1; NOD2, nucleotide oligomerization domain 2; NWD1, NACHT and WD repeat domain-containing protein 1; PAMP, pathogen-associated molecular pattern; PCa, prostate cancer; PGN, peptidoglycan; PMBCL, primary mediastinal large B-cell lymphoma; PRR, pattern recognition receptor; PYD, pyrin domain; RIP2, receptor-interacting protein 2; ROS, reactive oxygen species; TAK1, TGF- β -activated kinase 1; TLR, Toll-like receptor; TRAIL, tumor necrosis factor related apoptosis-inducing ligand; UVB, ultraviolet B.

References

- 1 Zhong, Y., Kinio, A. and Saleh, M. (2013) Functions of NOD-like receptors in human diseases. *Front. Immunol.* **4**, 333, <https://doi.org/10.3389/fimmu.2013.00333>
- 2 Akira, S., Uematsu, S. and Takeuchi, O. (2006) Pathogen recognition and innate immunity. *Cell* **124**, 783–801, <https://doi.org/10.1016/j.cell.2006.02.015>
- 3 Muñoz-Wolf, N. and Lavelle, E.C. (2016) Innate immune receptors. *Methods Mol. Biol.* **1417**, 1–43, https://doi.org/10.1007/978-1-4939-3566-6_1
- 4 Kanneganti, T.-D., Lamkanfi, M. and Núñez, G. (2007) Intracellular NOD-like receptors in host defense and disease. *Immunity* **27**, 549–559, <https://doi.org/10.1016/j.immuni.2007.10.002>
- 5 Ting, J.P.-Y., Lovering, R.C., Alnemri, E.S., Bertin, J., Boss, J.M., Davis, B.K. et al. (2008) The NLR gene family: a standard nomenclature. *Immunity* **28**, 285–287, <https://doi.org/10.1016/j.immuni.2008.02.005>
- 6 Sirisinha, S. (2011) Insight into the mechanisms regulating immune homeostasis in health and disease. *Asian Pac. J. Allergy Immunol.* **29**, 1–14
- 7 Creagh, E.M. and O'Neill, L.A.J. (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. *Trends Immunol.* **27**, 352–357, <https://doi.org/10.1016/j.it.2006.06.003>
- 8 Kim, Y.K., Shin, J.S. and Nahm, M.H. (2016) NOD-like receptors in infection, immunity, and diseases. *Yonsei Med. J.* **57**, 5–14, <https://doi.org/10.3349/ymj.2016.57.1.5>
- 9 Hoque, R. and Mehal, W.Z. (2015) Inflammasomes in pancreatic physiology and disease. *Am. J. Physiol. Gastrointest. Liver Physiol.* **308** (8), G643–G651, <https://doi.org/10.1152/ajpgi.00388.2014>
- 10 Kufer, T.A., Banks, D.J. and Philpott, D.J. (2006) Innate immune sensing of microbes by Nod proteins. *Ann. N.Y. Acad. Sci.* **1072**, 19–27, <https://doi.org/10.1196/annals.1326.020>

- 11 Craven, R.R., Gao, X., Allen, I.C., Gris, D., Bubeck Wardenburg, J., McElvania-Tekippe, E. et al. (2009) *Staphylococcus aureus* alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. *PLoS ONE* **4**, e7446, <https://doi.org/10.1371/journal.pone.0007446>
- 12 Muruve, D.A., Pétrilli, V., Zaiss, A.K., White, L.R., Clark, S.A., Ross, P.J. et al. (2008) The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. *Nature* **452**, 103–107, <https://doi.org/10.1038/nature06664>
- 13 Gross, O., Poeck, H., Bscheidler, M., Dostert, C., Hanneschläger, N., Endres, S. et al. (2009) Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. *Nature* **459**, 433–436, <https://doi.org/10.1038/nature07965>
- 14 Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M. et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* **440**, 228–232, <https://doi.org/10.1038/nature04515>
- 15 Yamasaki, K., Muto, J., Taylor, K.R., Cogen, A.L., Audish, D., Bertin, J. et al. (2009) NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. *J. Biol. Chem.* **284**, 12762–12771, <https://doi.org/10.1074/jbc.M806084200>
- 16 Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. and Tschopp, J. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* **440**, 237–241, <https://doi.org/10.1038/nature04516>
- 17 Murray, P.J. (2005) NOD proteins: an intracellular pathogen-recognition system or signal transduction modifiers? *Curr. Opin. Immunol.* **17**, 352–358, <https://doi.org/10.1016/j.coi.2005.05.006>
- 18 Martinon, F. and Tschopp, J. (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. *Cell Death Differ.* **14**, 10–22, <https://doi.org/10.1038/sj.cdd.4402038>
- 19 Pétrilli, V., Dostert, C., Muruve, D.A. and Tschopp, J. (2007) The inflammasome: a danger sensing complex triggering innate immunity. *Curr. Opin. Immunol.* **19**, 615–622, <https://doi.org/10.1016/j.coi.2007.09.002>
- 20 Tattoli, I., Travassos, L.H., Carneiro, L.A., Magalhaes, J.G. and Girardin, S.E. (2007) The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. *Semin. Immunopathol.* **29**, 289–301, <https://doi.org/10.1007/s00281-007-0083-2>
- 21 Travassos, L.H., Carneiro, L.A.M., Girardin, S. and Philpott, D.J. (2010) Nod proteins link bacterial sensing and autophagy. *Autophagy* **6**, 409–411, <https://doi.org/10.4161/auto.6.3.11305>
- 22 Proell, M., Riedl, S.J., Fritz, J.H., Rojas, A.M. and Schwarzenbacher, R. (2008) The Nod-like receptor (NLR) family: a tale of similarities and differences. *PLoS ONE* **3**, e2119, <https://doi.org/10.1371/journal.pone.0002119>
- 23 Harton, J.A., Linhoff, M.W., Zhang, J. and Ting, J.P.-Y. (2002) Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. *J. Immunol.* **169**, 4088–4093, <https://doi.org/10.4049/jimmunol.169.8.4088>
- 24 Inohara, N., Chamailard, M., McDonald, C. and Nuñez, G. (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. *Annu. Rev. Biochem.* **74**, 355–383, <https://doi.org/10.1146/annurev.biochem.74.082803.133347>
- 25 Carneiro, L.A.M., Magalhaes, J.G., Tattoli, I., Philpott, D.J. and Travassos, L.H. (2008) Nod-like proteins in inflammation and disease. *J. Pathol.* **214**, 136–148, <https://doi.org/10.1002/path.2271>
- 26 Huang, X.-P., Ludke, A., Dhingra, S., Guo, J., Sun, Z., Zhang, L. et al. (2016) Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart. *FASEB J.* **30**, 3069–3082, <https://doi.org/10.1096/fj.201600331R>
- 27 Morgan, J.E., Shanderson, R.L., Boyd, N.H., Cacan, E. and Greer, S.F. (2015) The class II transactivator (CIITA) is regulated by post-translational modification cross-talk between ERK1/2 phosphorylation, mono-ubiquitination and Lys63 ubiquitination. *Biosci. Rep.* **35** (4), <https://doi.org/10.1042/BSR20150091>
- 28 Raval, A., Howcroft, T.K., Weissman, J.D., Kirshner, S., Zhu, X.S., Yokoyama, K. et al. (2001) Transcriptional coactivator, CIITA, is an acetyltransferase that bypasses a promoter requirement for TAF(II)250. *Mol. Cell* **7**, 105–115, [https://doi.org/10.1016/S1097-2765\(01\)00159-9](https://doi.org/10.1016/S1097-2765(01)00159-9)
- 29 Maier, J.K.X., Lahoua, Z., Gendron, N.H., Fetni, R., Johnston, A., Davoodi, J. et al. (2002) The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. *J. Neurosci.* **22**, 2035–2043, <https://doi.org/10.1523/JNEUROSCI.22-06-02035.2002>
- 30 Davoodi, J., Ghahremani, M.-H., Es-Haghi, A., Mohammad-Gholi, A. and Mackenzie, A. (2010) Neuronal apoptosis inhibitory protein, NAIP, is an inhibitor of procaspase-9. *Int. J. Biochem. Cell Biol.* **42**, 958–964, <https://doi.org/10.1016/j.biocel.2010.02.008>
- 31 Abadía-Molina, F., Morón-Calvente, V., Baird, S.D., Shamim, F., Martín, F. and MacKenzie, A. (2017) Neuronal apoptosis inhibitory protein (NAIP) localizes to the cytokinetic machinery during cell division. *Sci. Rep.* **7**, 39981, <https://doi.org/10.1038/srep39981>
- 32 Motta, V., Soares, F., Sun, T. and Philpott, D.J. (2015) NOD-like receptors: versatile cytosolic sentinels. *Physiol. Rev.* **95**, 149–178, <https://doi.org/10.1152/physrev.00009.2014>
- 33 Correa, R.G., Milutinovic, S. and Reed, J.C. (2012) Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. *Biosci. Rep.* **32**, 597–608, <https://doi.org/10.1042/BSR20120055>
- 34 Kaparakis, M., Turnbull, L., Carneiro, L., Firth, S., Coleman, H.A., Parkington, H.C. et al. (2010) Bacterial membrane vesicles deliver peptidoglycan to NOD1 in epithelial cells. *Cell. Microbiol.* **12**, 372–385, <https://doi.org/10.1111/j.1462-5822.2009.01404.x>
- 35 Parker, H., Chitcholtan, K., Hampton, M.B. and Keenan, J.I. (2010) Uptake of *Helicobacter pylori* outer membrane vesicles by gastric epithelial cells. *Infect. Immun.* **78**, 5054–5061, <https://doi.org/10.1128/IAI.00299-10>
- 36 Chamailard, M., Hashimoto, M., Horie, Y., Masumoto, J., Qiu, S., Saab, L. et al. (2003) An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. *Nat. Immunol.* **4**, 702–707, <https://doi.org/10.1038/ni945>
- 37 Girardin, S.E., Boneca, I.G., Carneiro, L.A.M., Antignac, A., Jéhanno, M., Viala, J. et al. (2003) Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. *Science* **300**, 1584–1587, <https://doi.org/10.1126/science.1084677>
- 38 Philpott, D.J., Sorbara, M.T., Robertson, S.J., Croitoru, K. and Girardin, S.E. (2014) NOD proteins: regulators of inflammation in health and disease. *Nat. Rev. Immunol.* **14**, 9–23, <https://doi.org/10.1038/nri3565>

- 39 Stutz, A., Golenbock, D.T. and Latz, E. (2009) Science in medicine Inflammasomes: too big to miss. *J. Clin. Invest.* **119**, 3502–3511, <https://doi.org/10.1172/JCI40599>
- 40 Tian, X., Pascal, G. and Monget, P. (2009) Evolution and functional divergence of NLRP genes in mammalian reproductive systems. *BMC Evol. Biol.* **9**, 202, <https://doi.org/10.1186/1471-2148-9-202>
- 41 Kufer, T.A., Kremmer, E., Adam, A.C., Philpott, D.J. and Sansonetti, P.J. (2008) The pattern-recognition molecule Nod1 is localized at the plasma membrane at sites of bacterial interaction. *Cell. Microbiol.* **10**, 477–486
- 42 Legrand-Poels, S., Kustermans, G., Bex, F., Kremmer, E., Kufer, T.A. and Piette, J. (2007) Modulation of Nod2-dependent NF-kappaB signaling by the actin cytoskeleton. *J. Cell Sci.* **120**, 1299–1310, <https://doi.org/10.1242/jcs.03424>
- 43 Lee, J., Tattoli, I., Wojtal, K.A., Vavricka, S.R., Philpott, D.J. and Girardin, S.E. (2009) pH-dependent internalization of muramyl peptides from early endosomes enables Nod1 and Nod2 signaling. *J. Biol. Chem.* **284**, 23818–23829, <https://doi.org/10.1074/jbc.M109.033670>
- 44 Marina-García, N., Franchi, L., Kim, Y.-G., Hu, Y., Smith, D.E., Boons, G.-J. et al. (2009) Clathrin- and dynamin-dependent endocytic pathway regulates muramyl dipeptide internalization and NOD2 activation. *J. Immunol.* **182**, 4321–4327, <https://doi.org/10.4049/jimmunol.0802197>
- 45 Paik, D., Monahan, A., Caffrey, D.R., Elling, R., Goldman, W.E. and Silverman, N. (2017) SLC46 family transporters facilitate cytosolic innate immune recognition of monomeric peptidoglycans. *J. Immunol.* **199**, 263–270, <https://doi.org/10.4049/jimmunol.1600409>
- 46 Irving, A.T., Mimuro, H., Kufer, T.A., Lo, C., Wheeler, R., Turner, L.J. et al. (2014) The immune receptor NOD1 and kinase RIP2 interact with bacterial peptidoglycan on early endosomes to promote autophagy and inflammatory signaling. *Cell Host Microbe* **15**, 623–635, <https://doi.org/10.1016/j.chom.2014.04.001>
- 47 Nakamura, N., Lill, J.R., Phung, Q., Jiang, Z., Bakalarski, C., de Mazière, A. et al. (2014) Endosomes are specialized platforms for bacterial sensing and NOD2 signalling. *Nature* **509**, 240–244, <https://doi.org/10.1038/nature13133>
- 48 Sasawatari, S., Okamura, T., Kasumi, E., Tanaka-Furuyama, K., Yanabu-Takanashi, R., Shirasawa, S. et al. (2011) The solute carrier family 15A4 regulates TLR9 and NOD1 functions in the innate immune system and promotes colitis in mice. *Gastroenterology* **140**, 1513–1525, <https://doi.org/10.1053/j.gastro.2011.01.041>
- 49 Caruso, R., Warner, N., Inohara, N. and Núñez, G. (2014) NOD1 and NOD2: signaling, host defense, and inflammatory disease. *Immunity* **41**, 898–908, <https://doi.org/10.1016/j.immuni.2014.12.010>
- 50 Kobayashi, K., Inohara, N., Hernandez, L.D., Galán, J.E., Núñez, G., Janeway, C.A. et al. (2002) RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. *Nature* **416**, 194–199, <https://doi.org/10.1038/416194a>
- 51 McCarthy, J.V., Ni, J. and Dixit, V.M. (1998) RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. *J. Biol. Chem.* **273**, 16968–16975, <https://doi.org/10.1074/jbc.273.27.16968>
- 52 Marinis, J.M., Homer, C.R., McDonald, C. and Abbott, D.W. (2011) A novel motif in the Crohn's disease susceptibility protein, NOD2, allows TRAF4 to down-regulate innate immune responses. *J. Biol. Chem.* **286**, 1938–1950, <https://doi.org/10.1074/jbc.M110.189308>
- 53 Kim, J.-Y., Omori, E., Matsumoto, K., Núñez, G. and Ninomiya-Tsuji, J. (2008) TAK1 is a central mediator of NOD2 signaling in epidermal cells. *J. Biol. Chem.* **283**, 137–144, <https://doi.org/10.1074/jbc.M704746200>
- 54 Hasegawa, M., Fujimoto, Y., Lucas, P.C., Nakano, H., Fukase, K., Núñez, G. et al. (2008) A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. *EMBO J.* **27**, 373–383, <https://doi.org/10.1038/sj.emboj.7601962>
- 55 Hsu, Y.-M.S., Zhang, Y., You, Y., Wang, D., Li, H., Duramad, O. et al. (2007) The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. *Nat. Immunol.* **8**, 198–205, <https://doi.org/10.1038/ni1426>
- 56 Kobayashi, K.S., Chamailard, M., Ogura, Y., Henegariu, O., Inohara, N., Núñez, G. et al. (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science* **307**, 731–734, <https://doi.org/10.1126/science.1104911>
- 57 Travassos, L.H., Carneiro, L.A.M., Ramjeet, M., Hussey, S., Kim, Y.-G., Magalhães, J.G. et al. (2010) Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat. Immunol.* **11**, 55–62, <https://doi.org/10.1038/ni.1823>
- 58 Cooney, R., Baker, J., Brain, O., Danis, B., Pichulik, T., Allan, P. et al. (2010) NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. *Nat. Med.* **16**, 90–97, <https://doi.org/10.1038/nm.2069>
- 59 Homer, C.R., Kabi, A., Marina-García, N., Sreekumar, A., Nesvizhskii, A.I., Nickerson, K.P. et al. (2012) A dual role for receptor-interacting protein kinase 2 (RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy. *J. Biol. Chem.* **287**, 25565–25576, <https://doi.org/10.1074/jbc.M111.326835>
- 60 Keestra-Gounder, A.M. and Tsois, R.M. (2017) NOD1 and NOD2: beyond peptidoglycan sensing. *Trends Immunol.* **38**, 758–767, <https://doi.org/10.1016/j.it.2017.07.004>
- 61 Keestra-Gounder, A.M., Byndloss, M.X., Seyffert, N., Young, B.M., Chávez-Arroyo, A., Tsai, A.Y. et al. (2016) NOD1 and NOD2 signalling links ER stress with inflammation. *Nature* **532**, 394–397, <https://doi.org/10.1038/nature17631>
- 62 Bernales, S., McDonald, K.L. and Walter, P. (2006) Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response. *PLoS Biol.* **4**, e423, <https://doi.org/10.1371/journal.pbio.0040423>
- 63 Ding, W.-X., Ni, H.-M., Gao, W., Hou, Y.-F., Melan, M.A., Chen, X. et al. (2007) Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. *J. Biol. Chem.* **282**, 4702–4710, <https://doi.org/10.1074/jbc.M609267200>
- 64 Ogata, M., Hino, S., Saito, A., Morikawa, K., Kondo, S., Kanemoto, S. et al. (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. *Mol. Cell Biol.* **26**, 9220–9231, <https://doi.org/10.1128/MCB.01453-06>
- 65 Lee, W.-S., Yoo, W.-H. and Chae, H.-J. (2015) ER stress and autophagy. *Curr. Mol. Med.* **15**, 735–745, <https://doi.org/10.2174/1566524015666150921105453>
- 66 Lilienbaum, A. (2013) Relationship between the proteasomal system and autophagy. *Int. J. Biochem. Mol. Biol.* **4**, 1–26
- 67 Pashenkov, M.V., Dagil, Y.A. and Pinegin, B.V. (2018) NOD1 and NOD2: Molecular targets in prevention and treatment of infectious diseases. *Int. Immunopharmacol.* **54**, 385–400, <https://doi.org/10.1016/j.intimp.2017.11.036>

- 68 Vanaja, S.K., Rathinam, V. A.K. and Fitzgerald, K.A. (2015) Mechanisms of inflammasome activation: Recent advances and novel insights. *Trends Cell Biol.* **25**, 308–315, <https://doi.org/10.1016/j.tcb.2014.12.009>
- 69 Sharma, D. and Kanneganti, T.D. (2016) The cell biology of inflammasomes: Mechanisms of inflammasome activation and regulation. *J. Cell Biol.* **213**, 617–629, <https://doi.org/10.1083/jcb.201602089>
- 70 Latz, E. (2013) Activation and regulation of the inflammasomes Eicke. *Nat. Rev. Immunol.* **13**, <https://doi.org/10.1038/nri3452>
- 71 Ramachandran, R.A., Lupfer, C. and Zaki, H. (2018) The inflammasome: regulation of nitric oxide and antimicrobial host defence. *Adv. Microb. Physiol.* **72**, 65–115, <https://doi.org/10.1016/bs.ampbs.2018.01.004>
- 72 Naik, E. and Dixit, V.M. (2010) Modulation of inflammasome activity for the treatment of auto-inflammatory disorders. *J. Clin. Immunol.* **30**, 485–490, <https://doi.org/10.1007/s10875-010-9383-8>
- 73 Davis, B.K., Wen, H. and Ting, J.P.-Y. (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. *Annu. Rev. Immunol.* **29**, 707–735, <https://doi.org/10.1146/annurev-immunol-031210-101405>
- 74 Yin, X., Han, G.-C., Jiang, X.-W., Shi, Q. and Pu, C.-Q. (2016) Increased expression of the NOD-like receptor family, pyrin domain containing 3 inflammasome in dermatomyositis and polymyositis is a potential contributor to their pathogenesis. *Chin. Med. J. (Engl)*. **129**, 1047–1052, <https://doi.org/10.4103/0366-6999.180528>
- 75 Cookson, B.T. and Brennan, M.A. (2001) Pro-inflammatory programmed cell death. *Trends Microbiol.* **9**, 113–114, [https://doi.org/10.1016/S0966-842X\(00\)01936-3](https://doi.org/10.1016/S0966-842X(00)01936-3)
- 76 Bergsbaken, T., Fink, S.L. and Cookson, B.T. (2009) Pyroptosis: host cell death and inflammation. *Nat. Rev. Microbiol.* **7**, 99–109, <https://doi.org/10.1038/nrmicro2070>
- 77 Dinarello, C.A. (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood* **117**, 3720–3732, <https://doi.org/10.1182/blood-2010-07-273417>
- 78 Radian, A.D., de Almeida, L., Dorfleutner, A. and Stehlik, C. (2013) NLRP7 and related inflammasome activating pattern recognition receptors and their function in host defense and disease. *Microbes Infect.* **15**, 630–639, <https://doi.org/10.1016/j.micinf.2013.04.001>
- 79 Kerur, N., Veetil, M.V., Sharma-Walia, N., Bottero, V., Sadagopan, S., Otageri, P. et al. (2011) IFI16 acts as a nuclear pathogen sensor to induce the inflammasome in response to Kaposi Sarcoma-associated herpesvirus infection. *Cell Host Microbe* **9**, 363–375, <https://doi.org/10.1016/j.chom.2011.04.008>
- 80 Martinon, F., Burns, K. and Tschopp, J. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1 β . *Mol. Cell* **10**, 417–426, [https://doi.org/10.1016/S1097-2765\(02\)00599-3](https://doi.org/10.1016/S1097-2765(02)00599-3)
- 81 Jin, Y., Mailloux, C.M., Gowan, K., Riccardi, S.L., LaBerge, G., Bennett, D.C. et al. (2007) NALP1 in vitiligo-associated multiple autoimmune disease. *N. Engl. J. Med.* **356**, 1216–1225, <https://doi.org/10.1056/NEJMoa061592>
- 82 Masters, S.L., Lagou, V., Jéru, I., Baker, P.J., Van Eyck, L., Parry, D.A. et al. (2016) Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. *Sci. Transl. Med.* **8**, 332ra45, <https://doi.org/10.1126/scitranslmed.aaf1471>
- 83 Okamoto, M., Liu, W., Luo, Y., Tanaka, A., Cai, X., Norris, D.A. et al. (2010) Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1 β . *J. Biol. Chem.* **285**, 6477–6488, <https://doi.org/10.1074/jbc.M109.064907>
- 84 Chavarría-Smith, J. and Vance, R.E. (2015) The NLRP1 inflammasomes. *Immunol. Rev.* **265**, 22–34, <https://doi.org/10.1111/imr.12283>
- 85 Sastalla, I., Crown, D., Masters, S.L., McKenzie, A., Leppla, S.H. and Moayeri, M. (2013) Transcriptional analysis of the three Nlrp1 paralogs in mice. *BMC Genomics* **14**, 188, <https://doi.org/10.1186/1471-2164-14-188>
- 86 Boyden, E.D. and Dietrich, W.F. (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. *Nat. Genet.* **38**, 240–244, <https://doi.org/10.1038/ng1724>
- 87 Ewald, S.E., Chavarría-Smith, J. and Boothroyd, J.C. (2014) NLRP1 is an inflammasome sensor for *Toxoplasma gondii*. *Infect. Immun.* **82**, 460–468, <https://doi.org/10.1128/IAI.01170-13>
- 88 Szabo, G. and Csak, T. (2012) Inflammasomes in liver diseases. *J. Hepatol.* **57**, 642–654
- 89 Zhou, R., Yazdi, A.S., Menu, P. and Tschopp, J. (2011) A role for mitochondria in NLRP3 inflammasome activation. *Nature* **469**, 221–225, <https://doi.org/10.1038/nature09663>
- 90 Kanneganti, T.-D., Kundu, M. and Green, D.R. (2015) Innate immune recognition of mtDNA—an undercover signal? *Cell Metab.* **21**, 793–794, <https://doi.org/10.1016/j.cmet.2015.05.019>
- 91 Shimada, K., Crother, T.R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S. et al. (2012) Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. *Immunity* **36**, 401–414, <https://doi.org/10.1016/j.immuni.2012.01.009>
- 92 Sagulenko, V., Thygesen, S.J., Sester, D.P., Idris, A., Cridland, J.A., Vajjhala, P.R. et al. (2013) AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. *Cell Death Differ.* **20**, 1149–1160, <https://doi.org/10.1038/cdd.2013.37>
- 93 Shenoy, A. (2011) References and Notes 1. *Humanities* **333**, 481–486
- 94 Shenoy, A.R., Wellington, D.A., Kumar, P., Kassa, H., Booth, C.J., Cresswell, P. et al. (2012) GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. *Science* **336**, 481–485, <https://doi.org/10.1126/science.1217141>
- 95 Bauernfeind, F. and Hornung, V. (2013) Of inflammasomes and pathogens—sensing of microbes by the inflammasome. *EMBO Mol. Med.* **5**, 814–826, <https://doi.org/10.1002/emmm.201201771>
- 96 Franchi, L., Amer, A., Body-Malapel, M., Kanneganti, T.-D., Ozören, N., Jagirdar, R. et al. (2006) Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1 β in Salmonella-infected macrophages. *Nat. Immunol.* **7**, 576–582, <https://doi.org/10.1038/ni1346>
- 97 Miao, E.A., Mao, D.P., Yudkovsky, N., Bonneau, R., Lorang, C.G., Warren, S.E. et al. (2010) Innate immune detection of the type III secretion apparatus through the NLR4 inflammasome. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 3076–3080, <https://doi.org/10.1073/pnas.0913087107>

- 98 Afonina, I.S., Zhong, Z., Karin, M. and Beyaert, R. (2017) Limiting inflammation—the negative regulation of NF- κ B and the NLRP3 inflammasome. *Nat. Immunol.* **18**, 861–869, <https://doi.org/10.1038/ni.3772>
- 99 Grivennikov, S.I., Greten, F.R. and Karin, M. (2010) Immunity, inflammation, and cancer. *Cell.*, <https://doi.org/10.1016/j.cell.2010.01.025>
- 100 Trinchieri, G. (2012) Cancer and inflammation: an old intuition with rapidly evolving new concepts. *Annu. Rev. Immunol.* **30**, 677–706, <https://doi.org/10.1146/annurev-immunol-020711-075008>
- 101 Zambirinis, C.P., Pushalkar, S., Saxena, D. and Miller, G. (2014) Pancreatic cancer, inflammation, and microbiome. *Cancer J.* **20**, 195–202, <https://doi.org/10.1097/PP0.0000000000000045>
- 102 Multhoff, G., Molls, M. and Radons, J. (2011) Chronic inflammation in cancer development. *Front. Immunol.* **2**, 98
- 103 Tafani, M., Sansone, L., Limana, F., Arcangeli, T., De Santis, E., Polese, M. et al. (2016) The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. *Oxid. Med. Cell Longev.* **2016**, 3907147, <https://doi.org/10.1155/2016/3907147>
- 104 Jochems, C. and Schlom, J. (2011) Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. *Exp. Biol. Med.* **236**, 567–579, <https://doi.org/10.1258/ebm.2011.011007>
- 105 Levi, I., Amsalem, H., Nissan, A., Darash-Yahana, M., Peretz, T., Mandelboim, O. et al. (2015) Characterization of tumor infiltrating natural killer cell subset. *Oncotarget* **6**, 13835–13843, <https://doi.org/10.18632/oncotarget.3453>
- 106 Liu, Y., Tergaonkar, V., Krishna, S. and Androphy, E.J. (1999) Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. *J. Biol. Chem.* **274**, 24819–24827, <https://doi.org/10.1074/jbc.274.35.24819>
- 107 Akncilar, S.C., Khattar, E., Boon, P. L.S., Unal, B., Fullwood, M.J. and Tergaonkar, V. (2016) Long-range chromatin interactions drive mutant TERT promoter activation. *Cancer Discov.* **6**, 1276–1291, <https://doi.org/10.1158/2159-8290.CD-16-0177>
- 108 Li, Y., Cheng, H.S., Chng, W.J. and Tergaonkar, V. (2016) Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. *Proc. Natl. Acad. Sci. U.S.A.* **113**, 14402–14407, <https://doi.org/10.1073/pnas.1611106113>
- 109 Khattar, E., Kumar, P., Liu, C.Y., Akncilar, S.C., Raju, A., Lakshmanan, M. et al. (2016) Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. *J. Clin. Invest.* **126**, 4045–4060, <https://doi.org/10.1172/JCI86042>
- 110 Akncilar, S.C., Low, K.C., Liu, C.Y., Yan, T.D., Oji, A., Ikawa, M. et al. (2015) Quantitative assessment of telomerase components in cancer cell lines. *FEBS Lett.* **589**, 974–984, <https://doi.org/10.1016/j.febslet.2015.02.035>
- 111 Apps, J.R., Carreno, G., Gonzalez-Meljem, J.M., Haston, S., Guiho, R., Cooper, J.E. et al. (2018) Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. *Acta Neuropathol.* **135**, 757–777, <https://doi.org/10.1007/s00401-018-1830-2>
- 112 Janssen, L.M.E., Ramsay, E.E., Logsdon, C.D. and Overwijk, W.W. (2017) The immune system in cancer metastasis: friend or foe? *J. Immunother. Cancer* **5**, 79, <https://doi.org/10.1186/s40425-017-0283-9>
- 113 Stockmann, C., Schadendorf, D., Klose, R. and Helfrich, I. (2014) The impact of the immune system on tumor: angiogenesis and vascular remodeling. *Front. Oncol.* **4**, 69, <https://doi.org/10.3389/fonc.2014.00069>
- 114 Hoesel, B. and Schmid, J.A. (2013) The complexity of NF- κ B signaling in inflammation and cancer. *Mol. Cancer* **12**, 86, <https://doi.org/10.1186/1476-4598-12-86>
- 115 Dey, A., Wong, E., Kua, N., Teo, H.L., Tergaonkar, V. and Lane, D. (2008) Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. *Cell Cycle* **7**, 3759–3767, <https://doi.org/10.4161/cc.7.23.7213>
- 116 Tak, P.P. and Firestein, G.S. (2001) NF-kappaB: a key role in inflammatory diseases. *J. Clin. Invest.* **107**, 7–11, <https://doi.org/10.1172/JCI11830>
- 117 Baker, R.G., Hayden, M.S. and Ghosh, S. (2011) NF- κ B, inflammation, and metabolic disease. *Cell Metab.* **13**, 11–22, <https://doi.org/10.1016/j.cmet.2010.12.008>
- 118 Espín-Palazón, R. and Traver, D. (2016) The NF- κ B family: key players during embryonic development and HSC emergence. *Exp. Hematol.* **44**, 519–527, <https://doi.org/10.1016/j.exphem.2016.03.010>
- 119 Bushdid, P.B., Brantley, D.M., Yull, F.E., Blaeuer, G.L., Hoffman, L.H., Niswander, L. et al. (1998) Inhibition of NF-kappaB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. *Nature* **392**, 615–618, <https://doi.org/10.1038/33435>
- 120 Tobe, M., Isobe, Y., Tomizawa, H., Nagasaki, T., Takahashi, H., Fukazawa, T. et al. (2003) Discovery of quinazolines as a novel structural class of potent inhibitors of NF-kappa B activation. *Bioorg. Med. Chem.* **11**, 383–391, [https://doi.org/10.1016/S0968-0896\(02\)00440-6](https://doi.org/10.1016/S0968-0896(02)00440-6)
- 121 Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S. and Baltimore, D. (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. *Nature* **376**, 167–170, <https://doi.org/10.1038/376167a0>
- 122 Grossmann, M., Metcalf, D., Merryfull, J., Beg, A., Baltimore, D. and Gerondakis, S. (1999) The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 11848–11853, <https://doi.org/10.1073/pnas.96.21.11848>
- 123 Correa, R.G., Matsui, T., Tergaonkar, V., Rodriguez-Esteban, C., Izpisua-Belmonte, J.C. and Verma, I.M. (2005) Zebrafish IkappaB kinase 1 negatively regulates NF-kappaB activity. *Curr. Biol.* **15**, 1291–1295, <https://doi.org/10.1016/j.cub.2005.06.023>
- 124 Woronicz, J.D., Gao, X., Cao, Z., Rothe, M. and Goeddel, D.V. (1997) IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. *Science* **278**, 866–869, <https://doi.org/10.1126/science.278.5339.866>
- 125 Li, Q., Van Antwerp, D., Mercurio, F., Lee, K.F. and Verma, I.M. (1999) Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. *Science* **284**, 321–325, <https://doi.org/10.1126/science.284.5412.321>
- 126 Correa, R.G., Tergaonkar, V., Ng, J.K., Dubova, I., Izpisua-Belmonte, J.C. and Verma, I.M. (2004) Characterization of NF-kappa B/I kappa B proteins in zebra fish and their involvement in notochord development. *Mol. Cell. Biol.* **24**, 5257–5268, <https://doi.org/10.1128/MCB.24.12.5257-5268.2004>
- 127 Dunleavy, K. and Wilson, W.H. (2015) Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? *Blood* **125**, 33–39, <https://doi.org/10.1182/blood-2014-05-575092>

- 128 Mottok, A., Woolcock, B., Chan, F.C., Tong, K.M., Chong, L., Farinha, P. et al. (2015) Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II Expression. *Cell Rep.* **13**, 1418–1431, <https://doi.org/10.1016/j.celrep.2015.10.008>
- 129 Steidl, C., Shah, S.P., Woolcock, B.W., Rui, L., Kawahara, M., Farinha, P. et al. (2011) MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. *Nature* **471**, 377–381, <https://doi.org/10.1038/nature09754>
- 130 Janczur Velloso, F., Filipini Rodrigues Bianco, A., Farias, J.O., Torres, N.E., Ferruzo, P.Y., Anschau, V. et al. (2017) The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. *Onco Targets Ther.* **10**, 5491–5524, <https://doi.org/10.2147/OTT.S142154>
- 131 Choi, J., Hwang, Y.K., Choi, Y.J., Yoo, K. H.E., Kim, J.H., Nam, S.J. et al. (2007) Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. *J. Korean Med. Sci.* **22**, S17–S23, <https://doi.org/10.3346/jkms.2007.22.S.S17>
- 132 Hagggar, F.A. and Boushey, R.P. (2009) Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin. Colon Rectal Surg.* **22**, 191–197, <https://doi.org/10.1055/s-0029-1242458>
- 133 Ansa, B.E., Coughlin, S.S., Alema-Mensah, E. and Smith, S.A. (2018) Evaluation of colorectal cancer incidence trends in the United States (2000–2014). *J. Clin. Med.* **7**, 630–639, <https://doi.org/10.3390/jcm7020022>
- 134 Allam, R., Maillard, M.H., Tardivel, A., Chennupati, V., Bega, H., Yu, C.W. et al. (2015) Epithelial NAIPIs protect against colonic tumorigenesis. *J. Exp. Med.* **212**, 369–383, <https://doi.org/10.1084/jem.20140474>
- 135 Endo, T., Abe, S., Seidler, H.B., Nagaoka, S., Takemura, T., Utsuyama, M. et al. (2004) Expression of IAP family proteins in colon cancers from patients with different age groups. *Cancer Immunol. Immunother.* **53**, 770–776, <https://doi.org/10.1007/s00262-004-0534-8>
- 136 Wong, M.C., Goggins, W.B., Wang, H.H., Fung, F.D., Leung, C., Wong, S.Y. et al. (2016) Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. *Eur. Urol.* **70**, 862–874, <https://doi.org/10.1016/j.eururo.2016.05.043>
- 137 da Silva, H.B., Amaral, E.P., Nolasco, E.L., de Victo, N.C., Atique, R., Jank, C.C. et al. (2013) Dissecting major signaling pathways throughout the development of prostate cancer. *Prostate Cancer* **2013**, 920612, <https://doi.org/10.1155/2013/920612>
- 138 Chiu, H.H., Yong, T.M., Wang, J., Wang, Y.Z., Vessella, R.L., Ueda, T. et al. (2010) Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer. *Cancer Lett.* **292**, 176–185, <https://doi.org/10.1016/j.canlet.2009.11.023>
- 139 Cinar, B., Yeung, F., Konaka, H., Mayo, M.W., Freeman, M.R., Zhau, H.E. et al. (2004) Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. *Biochem. J.* **379**, 421–431, <https://doi.org/10.1042/bj20031661>
- 140 Rose, D.P. and Vona-Davis, L. (2009) Influence of obesity on breast cancer receptor status and prognosis. *Expert Rev. Anticancer Ther.* **9**, 1091–1101, <https://doi.org/10.1586/era.09.71>
- 141 Kolb, R., Phan, L., Borchering, N., Liu, Y., Yuan, F., Janowski, A.M. et al. (2016) Obesity-associated NLR4 inflammasome activation drives breast cancer progression. *Nat. Commun.* **7**, 13007, <https://doi.org/10.1038/ncomms13007>
- 142 Kutikhin, A.G. (2011) Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. *Hum. Immunol.* **72**, 955–968, <https://doi.org/10.1016/j.humimm.2011.06.003>
- 143 Liu, J., He, C., Xu, Q., Xing, C. and Yuan, Y. (2014) NOD2 polymorphisms associated with cancer risk: a meta-analysis. *PLoS ONE* **9**, e89340, <https://doi.org/10.1371/journal.pone.0089340>
- 144 da Silva Correia, J., Miranda, Y., Austin-Brown, N., Hsu, J., Mathison, J., Xiang, R. et al. (2006) Nod1-dependent control of tumor growth. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 1840–1845, <https://doi.org/10.1073/pnas.0509228103>
- 145 da Silva Correia, J., Miranda, Y., Leonard, N., Hsu, J. and Ulevitch, R.J. (2007) Regulation of Nod1-mediated signaling pathways. *Cell Death Differ.* **14**, 830–839, <https://doi.org/10.1038/sj.cdd.4402070>
- 146 Velloso, F.J., Sogayar, M.C. and Correa, R.G. (2018) Expression and in vitro assessment of tumorigenicity for NOD1 and NOD2 receptors in breast cancer cell lines. *BMC Res. Notes* **11**, 222, <https://doi.org/10.1186/s13104-018-3335-4>
- 147 Velloso, F.J., Campos, A.R., Sogayar, M.C. and Correa, R.G. (2019) Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation. *BMC Genomics* **20**, 152, <https://doi.org/10.1186/s12864-019-5523-6>
- 148 Liu, R., Truax, A.D., Chen, L., Hu, P., Li, Z., Chen, J. et al. (2015) Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. *Oncotarget* **6**, 33456–33469
- 149 Yoshihama, S., Roszik, J., Downs, I., Meissner, T.B., Vijayan, S., Chapuy, B. et al. (2016) NLR5/MHC class I transactivator is a target for immune evasion in cancer. *Proc. Natl. Acad. Sci. U.S.A.* **113**, 5999–6004, <https://doi.org/10.1073/pnas.1602069113>
- 150 Zhan, Y., Seregin, S.S., Chen, J. and Chen, G.Y. (2016) Nod1 limits colitis-associated tumorigenesis by regulating IFN- γ production. *J. Immunol.* **196**, 5121–5129, <https://doi.org/10.4049/jimmunol.1501822>
- 151 Karki, R., Malireddi, R.K.S., Zhu, Q. and Kanneganti, T.D. (2017) NLR3 regulates cellular proliferation and apoptosis to attenuate the development of colorectal cancer. *Cell Cycle* **16**, 1243–1251, <https://doi.org/10.1080/15384101.2017.1317414>
- 152 Hu, B., Elinav, E., Huber, S., Booth, C.J., Strowig, T., Jin, C. et al. (2010) Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLR4. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 21635–21640, <https://doi.org/10.1073/pnas.1016814108>
- 153 Ozcan, M., Janikovits, J., von Knebel Doeberitz, M. and Kloor, M. (2018) Complex pattern of immune evasion in MSI colorectal cancer. *Oncimmunology* **7**, e1445453, <https://doi.org/10.1080/2162402X.2018.1445453>
- 154 Catalano, C., da Silva Filho, M.I., Frank, C., Jiraskova, K., Vymetalkova, V., Levy, M. et al. (2018) Investigation of single and synergic effects of NLR5 and PD-L1 variants on the risk of colorectal cancer. *PLoS ONE* **13**, e0192385, <https://doi.org/10.1371/journal.pone.0192385>
- 155 Huhn, S., da Silva Filho, M.I., Sanmuganantham, T., Pichulik, T., Catalano, C., Pardini, B. et al. (2018) Coding variants in NOD-like receptors: an association study on risk and survival of colorectal cancer. *PLoS ONE* **13**, e0199350, <https://doi.org/10.1371/journal.pone.0199350>
- 156 Udden, S. M.N., Peng, L., Gan, J.L., Shelton, J.M., Malter, J.S., Hooper, L.V. et al. (2017) NOD2 suppresses colorectal tumorigenesis via downregulation of the TLR pathways. *Cell Rep.* **19**, 2756–2770, <https://doi.org/10.1016/j.celrep.2017.05.084>

- 157 Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A., Haesler, R. et al. (2013) NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. *J. Clin. Invest.* **123**, 700–711
- 158 Ishaq, S. and Nunn, L. (2015) Helicobacter pylori and gastric cancer: a state of the art review. *Gastroenterol. Hepatol.* **8**, S6–S14
- 159 Li, Z.X., Wang, Y.M., Tang, F.B., Zhang, L., Zhang, Y., Ma, J.L. et al. (2015) NOD1 and NOD2 genetic variants in association with risk of gastric cancer and its precursors in a Chinese population. *PLoS ONE* **10**, e0124949, <https://doi.org/10.1371/journal.pone.0124949>
- 160 Asano, N., Imatani, A., Watanabe, T., Fushiya, J., Kondo, Y., Jin, X. et al. (2016) Cdx2 expression and intestinal metaplasia induced by H. pylori infection of gastric cells is regulated by NOD1-mediated innate immune responses. *Cancer Res.* **76**, 1135–1145, <https://doi.org/10.1158/0008-5472.CAN-15-2272>
- 161 Suarez, G., Romero-Gallo, J., Piazuolo, M.B., Wang, G., Maier, R.J., Forsberg, L.S. et al. (2015) Modification of Helicobacter pylori peptidoglycan enhances NOD1 activation and promotes cancer of the stomach. *Cancer Res.* **75**, 1749–1759, <https://doi.org/10.1158/0008-5472.CAN-14-2291>
- 162 Li, Y., Zhang, M. and Zheng, X. (2018) High expression of NLRP5 is associated with prognosis of gastric cancer. *Open Med.* **13**, 443–449, <https://doi.org/10.1515/med-2018-0066>
- 163 Moossavi, M., Parsamanesh, N., Bahrami, A., Atkin, S.L. and Sahebkar, A. (2018) Role of the NLRP3 inflammasome in cancer. *Mol. Cancer* **17**, 158, <https://doi.org/10.1186/s12943-018-0900-3>
- 164 Ribeiro, A.A., Costa, M.C., Alves, R.R., Villa, L.L., Saddi, V.A., Carneiro, M.A. et al. (2015) HPV infection and cervical neoplasia: associated risk factors. *Infect. Agent Cancer* **10**, 16, <https://doi.org/10.1186/s13027-015-0011-3>
- 165 de Castro-Sobrinho, J.M., Rabelo-Santos, S.H., Figueiredo-Alves, R.R., Derchain, S., Sarian, L.O., Pitta, D.R. et al. (2016) Bacterial vaginosis and inflammatory response showed association with severity of cervical neoplasia in HPV-positive women. *Diagn. Cytopathol.* **44**, 80–86, <https://doi.org/10.1002/dc.23388>
- 166 Pontillo, A., Bricher, P., Leal, V.N., Lima, S., Souza, P.R. and Crovella, S. (2016) Role of inflammasome genetics in susceptibility to HPV infection and cervical cancer development. *J. Med. Virol.* **88**, 1646–1651, <https://doi.org/10.1002/jmv.24514>
- 167 He, A., Shao, J., Zhang, Y., Lu, H., Wu, Z. and Xu, Y. (2017) CD200Fc reduces LPS-induced IL-1 β activation in human cervical cancer cells by modulating TLR4-NF- κ B and NLRP3 inflammasome pathway. *Oncotarget* **8**, 33214–33224
- 168 Zaki, M.H., Vogel, P., Malireddi, R.K., Body-Malapel, M., Anand, P.K., Bertin, J. et al. (2011) The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. *Cancer Cell* **20**, 649–660, <https://doi.org/10.1016/j.ccr.2011.10.022>
- 169 Du, Q., Wang, Q., Fan, H., Wang, J., Liu, X., Wang, H. et al. (2016) Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome. *Biochem. Pharmacol.* **105**, 42–54, <https://doi.org/10.1016/j.bcp.2016.02.017>
- 170 Liu, L., Dong, W., Wang, S., Zhang, Y., Liu, T., Xie, R. et al. (2018) Deoxycholic acid disrupts the intestinal mucosal barrier and promotes intestinal tumorigenesis. *Food Funct.* **9**, 5588–5597, <https://doi.org/10.1039/C8FO01143E>
- 171 Deng, Q., Geng, Y., Zhao, L., Li, R., Zhang, Z., Li, K. et al. (2018) NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver. *Cancer Lett.* **442**, 21–30, <https://doi.org/10.1016/j.canlet.2018.10.030>
- 172 Zhao, Y., Guo, Q., Zhao, K., Zhou, Y., Li, W., Pan, C. et al. (2017) Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy. *Oncoimmunology* **7**, e1375640, <https://doi.org/10.1080/2162402X.2017.1375640>
- 173 Wang, H., Wang, Y., Du, Q., Lu, P., Fan, H., Lu, J. et al. (2016) Inflammasome-independent NLRP3 is required for epithelial-mesenchymal transition in colon cancer cells. *Exp. Cell Res.* **342**, 184–192, <https://doi.org/10.1016/j.yexcr.2016.03.009>
- 174 Zaki, M.H., Vogel, P., Body-Malapel, M., Lamkanfi, M. and Kanneganti, T.D. (2010) IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. *J. Immunol.* **185**, 4912–4920, <https://doi.org/10.4049/jimmunol.1002046>
- 175 Dupaul-Chicoine, J., Arabzadeh, A., Dagenais, M., Douglas, T., Champagne, C., Morizot, A. et al. (2015) The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. *Immunity* **43**, 751–763, <https://doi.org/10.1016/j.immuni.2015.08.013>
- 176 Kim, J.Y., Kim, Y.M., Park, J.M., Han, Y.M., Lee, K.C., Hahm, K.B. et al. (2018) Cancer preventive effect of recombinant TRAIL by ablation of oncogenic inflammation in colitis-associated cancer rather than anticancer effect. *Oncotarget* **9**, 1705–1716
- 177 Amarante-Mendes, G.P. and Griffith, T.S. (2015) Therapeutic applications of TRAIL receptor agonists in cancer and beyond. *Pharmacol. Ther.* **155**, 117–131, <https://doi.org/10.1016/j.pharmthera.2015.09.001>
- 178 de Miguel, D., Lemke, J., Anel, A., Walczak, H. and Martinez-Lostao, L. (2016) Onto better TRAILs for cancer treatment. *Cell Death Differ.* **23**, 733–747, <https://doi.org/10.1038/cdd.2015.174>
- 179 Normand, S., Delanoye-Crespin, A., Bressenot, A., Huot, L., Grandjean, T., Peyrin-Biroulet, L. et al. (2011) Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 9601–9606, <https://doi.org/10.1073/pnas.1100981108>
- 180 Huber, S., Gagliani, N., Zenewicz, L.A., Huber, F.J., Bosurgi, L., Hu, B. et al. (2012) IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. *Nature* **491**, 259–263, <https://doi.org/10.1038/nature11535>
- 181 Zaki, M.H., Lamkanfi, M. and Kanneganti, T.D. (2011) The Nlrp3 inflammasome: contributions to intestinal homeostasis. *Trends Immunol.* **32**, 171–179, <https://doi.org/10.1016/j.it.2011.02.002>
- 182 Allen, I.C., Wilson, J.E., Schneider, M., Lich, J.D., Roberts, R.A., Arthur, J.C. et al. (2012) NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF- κ B signaling. *Immunity* **36**, 742–754, <https://doi.org/10.1016/j.immuni.2012.03.012>
- 183 Lortet-Tieulent, J., Ferlay, J., Bray, F. and Jemal, A. (2018) International patterns and trends in endometrial cancer incidence, 1978–2013. *J. Natl. Cancer Inst.* **110**, 354–361, <https://doi.org/10.1093/jnci/djx214>
- 184 Sorosky, J.I. (2012) Endometrial cancer. *Obstet. Gynecol.* **120**, 383–397, <https://doi.org/10.1097/AOG.0b013e3182605bf1>
- 185 Symons, L.K., Miller, J.E., Kay, V.R., Marks, R.M., Liblik, K., Koti, M. et al. (2018) The immunopathophysiology of endometriosis. *Trends Mol. Med.* **24**, 748–762, <https://doi.org/10.1016/j.molmed.2018.07.004>

- 186 Keita, M., Bessette, P., Pelmus, M., Ainmelk, Y. and Aris, A. (2010) Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. *J. Ovarian Res.* **3**, 3, <https://doi.org/10.1186/1757-2215-3-3>
- 187 Ohno, S., Kinoshita, T., Ohno, Y., Minamoto, T., Suzuki, N., Inoue, M. et al. (2008) Expression of NLRP7 (PYPAF3, NALP7) protein in endometrial cancer tissues. *Anticancer Res.* **28**, 2493–2497
- 188 Sitarz, R., Skierucha, M., Mielko, J., Offerhaus, G. J.A., Maciejewski, R. and Polkowski, W.P. (2018) Gastric cancer: epidemiology, prevention, classification, and treatment. *Cancer Manag. Res.* **10**, 239–248, <https://doi.org/10.2147/CMAR.S149619>
- 189 Castañero-Rodríguez, N., Kaakoush, N.O., Goh, K.L., Fock, K.M. and Mitchell, H.M. (2014) The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. *PLoS ONE* **9**, e98899, <https://doi.org/10.1371/journal.pone.0098899>
- 190 Li, S., Liang, X., Ma, L., Shen, L., Li, T., Zheng, L. et al. (2018) MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis. *Oncogene* **37**, 884–896, <https://doi.org/10.1038/nc.2017.381>
- 191 Wang, H., Xu, G., Huang, Z., Li, W., Cai, H., Zhang, Y. et al. (2017) LRP6 targeting suppresses gastric tumorigenesis via P14. *Oncotarget* **8**, 111597–111607, <https://doi.org/10.18632/oncotarget.22876>
- 192 Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K. et al. (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* **131**, 803–820, <https://doi.org/10.1007/s00401-016-1545-1>
- 193 Miranda-Filho, A., Piñeros, M., Soerjomataram, I., Deltour, I. and Bray, F. (2017) Cancers of the brain and CNS: global patterns and trends in incidence. *Neuro Oncol.* **19**, 270–280
- 194 Schwartzbaum, J.A., Fisher, J.L., Aldape, K.D. and Wrensch, M. (2006) Epidemiology and molecular pathology of glioma. *Nat. Clin. Pr. Neurol.* **2**, 494–503, <https://doi.org/10.1038/ncpneuro0289>
- 195 Dolecek, T.A., Propp, J.M., Stroup, N.E. and Kruchko, C. (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. *Neuro Oncol.* **14**, v1–v49, <https://doi.org/10.1093/neuonc/nos218>
- 196 Poon, C.C., Sarkar, S., Yong, V.W. and Kelly, J.J.P. (2017) Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. *Brain* **140**, 1548–1560, <https://doi.org/10.1093/brain/aww355>
- 197 Tarassishin, L., Lim, J., Weatherly, D.B., Angeletti, R.H. and Lee, S.C. (2014) Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression. *J. Proteomics* **99**, 152–168, <https://doi.org/10.1016/j.jprot.2014.01.024>
- 198 Tarassishin, L., Casper, D. and Lee, S.C. (2014) Aberrant expression of interleukin-1 β and inflammasome activation in human malignant gliomas. *PLoS ONE* **9**, e103432, <https://doi.org/10.1371/journal.pone.0103432>
- 199 Yin, X.F., Zhang, Q., Chen, Z.Y., Wang, H.F., Li, X., Wang, H.X. et al. (2018) NLRP3 in human glioma is correlated with increased WHO grade, and regulates cellular proliferation, apoptosis and metastasis via epithelial-mesenchymal transition and the PTEN/AKT signaling pathway. *Int. J. Oncol.* **53**, 973–986
- 200 Li, L. and Liu, Y. (2015) Aging-related gene signature regulated by Nlrp3 predicts glioma progression. *Am. J. Cancer Res.* **5**, 442–449
- 201 Shang, S., Wang, L., Zhang, Y., Lu, H. and Lu, X. (2018) The beta-hydroxybutyrate suppresses the migration of glioma cells by inhibition of NLRP3 inflammasome. *Cell Mol. Neurobiol.*, <https://doi.org/10.1007/s10571-018-0617-2>
- 202 Ding, Q., Shen, L., Nie, X., Lu, B., Pan, X., Su, Z. et al. (2018) MiR-223-3p overexpression inhibits cell proliferation and migration by regulating inflammation-associated cytokines in glioblastomas. *Pathol. Res. Pr.* **214**, 1330–1339, <https://doi.org/10.1016/j.prp.2018.05.012>
- 203 Moreira, D.M., Nickel, J.C., Andriole, G.L., Castro-Santamaria, R. and Freedland, S.J. (2015) Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study. *Prostate* **75**, 1492–1498, <https://doi.org/10.1002/pros.23041>
- 204 Yun, B.H., Hwang, E.C., Yu, H.S., Chung, H., Kim, S.O., Jung, S.I. et al. (2015) Is histological prostate inflammation in an initial prostate biopsy a predictor of prostate cancer on repeat biopsy? *Int. Urol. Nephrol.* **47**, 1251–1257, <https://doi.org/10.1007/s11255-015-1029-6>
- 205 Kashyap, M., Pore, S., Wang, Z., Gingrich, J., Yoshimura, N. and Tyagi, P. (2015) Inflammasomes are important mediators of prostatic inflammation associated with BPH. *J. Inflamm.* **12**, 37, <https://doi.org/10.1186/s12950-015-0082-3>
- 206 Fujita, K., Ewing, C.M., Isaacs, W.B. and Pavlovich, C.P. (2011) Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. *Int. J. Cancer* **129**, 424–432, <https://doi.org/10.1002/ijc.25705>
- 207 Dantonio, P.M., Klein, M.O., Freire, M.R.V.B., Araujo, C.N., Chiaccetti, A.C. and Correa, R.G. (2018) Exploring major signaling cascades in melanomagenesis: a rationale route for targeted skin cancer therapy. *Biosci. Rep.* **38** (5), <https://doi.org/10.1042/BSR20180511>
- 208 Linares, M.A., Zakaria, A. and Nizran, P. (2015) Skin cancer. *Prim. Care* **42**, 645–659, <https://doi.org/10.1016/j.pop.2015.07.006>
- 209 Zhong, F.L., Mamaï, O., Sborgi, L., Bousofara, L., Hopkins, R., Robinson, K. et al. (2016) Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. *Cell* **167**, 187–202.e17, <https://doi.org/10.1016/j.cell.2016.09.001>
- 210 Zhai, Z., Liu, W., Kaur, M., Luo, Y., Domenico, J., Samson, J.M. et al. (2017) NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. *Oncogene* **36**, 3820–3830, <https://doi.org/10.1038/nc.2017.26>
- 211 Hasegawa, T., Nakashima, M. and Suzuki, Y. (2016) Nuclear DNA damage-triggered NLRP3 inflammasome activation promotes UVB-induced inflammatory responses in human keratinocytes. *Biochem. Biophys. Res. Commun.* **477**, 329–335, <https://doi.org/10.1016/j.bbrc.2016.06.106>
- 212 Sollberger, G., Strittmatter, G.E., Grossi, S., Garstkiewicz, M., dem Keller, U., French, L.E. et al. (2015) Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. *J. Invest. Dermatol.* **135**, 1395–1404, <https://doi.org/10.1038/jid.2014.551>
- 213 Verma, D., Bivik, C., Farahani, E., Synnerstad, I., Fredrikson, M., Enerbäck, C. et al. (2012) Inflammasome polymorphisms confer susceptibility to sporadic malignant melanoma. *Pigment Cell Melanoma Res.* **25**, 506–513, <https://doi.org/10.1111/j.1755-148X.2012.01008.x>
- 214 Fenini, G., Grossi, S., Contassot, E., Biedermann, T., Reichmann, E., French, L.E. et al. (2018) Genome editing of human primary keratinocytes by CRISPR/Cas9 reveals an essential role of the NLRP1 inflammasome in UVB sensing. *J. Invest. Dermatol.* **138**, 2644–2652, <https://doi.org/10.1016/j.jid.2018.07.016>

- 215 Ahmad, I., Muneer, K.M., Tamimi, I.A., Chang, M.E., Ata, M.O. and Yusuf, N. (2013) Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome. *Toxicol. Appl. Pharmacol.* **270**, 70–76, <https://doi.org/10.1016/j.taap.2013.03.027>
- 216 Stein, C., Caccamo, M., Laird, G. and Leptin, M. (2007) Conservation and divergence of gene families encoding components of innate immune response systems in zebrafish. *Genome Biol.* **8**, R251, <https://doi.org/10.1186/gb-2007-8-11-r251>
- 217 Zou, H., Henzel, W.J., Liu, X., Lutschg, A. and Wang, X. (1997) Apaf-1, a human protein homologous to *C. elegans* CED-4, participates in cytochrome c-dependent activation of caspase-3. *Cell* **90**, 405–413, [https://doi.org/10.1016/S0092-8674\(00\)80501-2](https://doi.org/10.1016/S0092-8674(00)80501-2)
- 218 Chereau, D., Zou, H., Spada, A.P. and Wu, J.C. (2005) A nucleotide binding site in caspase-9 regulates apoptosome activation. *Biochemistry* **44**, 4971–4976, <https://doi.org/10.1021/bi047360+>
- 219 Correa, R.G., Krajewska, M., Ware, C.F., Gerlic, M. and Reed, J.C. (2014) The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling. *Oncotarget* **5**, 1666–1682, <https://doi.org/10.18632/oncotarget.1850>